cats20170930

0001437749-17-019351.txt : 20171114 0001437749-17-019351.hdr.sgml : 20171114 20171114160733 ACCESSION NUMBER: 0001437749-17-019351 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171114 DATE AS OF CHANGE: 20171114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATASYS, INC. CENTRAL INDEX KEY: 0001136174 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 880464853 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31932 FILM NUMBER: 171201511 BUSINESS ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 310 444 4300 MAIL ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: HYTHIAM, INC. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: HYTHIAM INC DATE OF NAME CHANGE: 20031003 FORMER COMPANY: FORMER CONFORMED NAME: ALASKA FREIGHTWAYS INC DATE OF NAME CHANGE: 20010305 10-Q 1 cats20170930_10q.htm FORM 10-Q cats20170930_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

Commission File Number 001-31932

_______________________

CATASYS, INC.

(Exact name of registrant as specified in its charter)

_______________________

Delaware	88-0464853
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

11601 Wilshire Boulevard, Suite 1100, Los Angeles, California 90025

(Address of principal executive offices, including zip code)

(310) 444-4300

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes☑ No☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes☑ No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,’’ “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☑ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes☐ No☑

As of November 13, 2017, there were 15,889,171 shares of the registrant's common stock, $0.0001 par value per share, outstanding.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION			3

	ITEM 1. Financial Statements		3

		Condensed Consolidated Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016	3

		Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2017 and 2016 (unaudited)	4

		Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (unaudited)	5

		Notes to Condensed Consolidated Financial Statements	6

	ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		15

	ITEM 3. Quantitative and Qualitative Disclosures About Market Risk		22

	ITEM 4. Controls and Procedures		22

PART II – OTHER INFORMATION			23

	ITEM 1. Legal Proceedings		23

	ITEM 1A. Risk Factors		23

	ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds		23

	ITEM 3. Defaults Upon Senior Securities		23

	ITEM 4. Mine Safety Disclosures		23

	ITEM 5. Other Information		23

	ITEM 6. Exhibits		23

In this Quarterly Report on Form 10-Q, except as otherwise stated or the context otherwise requires, the terms “we,” “us,” “our” or the “Company” refer to Catasys, Inc. and our wholly-owned subsidiaries. Our common stock, par value $0.0001 per share, is referred to as “common stock.”

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	(unaudited)
(In thousands, except for number of shares)	September 30,			December 31,
	2017			2016
ASSETS
Current assets
Cash and cash equivalents	$	6,926		$	851
Receivables, net of allowance for doubtful accounts of $277 and $0, respectively		709			1,052
Prepaids and other current assets		307			420
Total current assets		7,942			2,323
Long-term assets
Property and equipment, net of accumulated depreciation of $1,751 and $1,620, respectively		553			410
Deposits and other assets		371			371
Total Assets	$	8,866		$	3,104

LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)
Current liabilities
Accounts payable	$	806		$	870
Accrued compensation and benefits		901			2,089
Deferred revenue		3,180			1,525
Other accrued liabilities		579			575
Short term debt, related party, net of discount $0 and $216, respectively		-			9,796
Derivative liability		-			8,122
Total current liabilities		5,466			22,977
Long-term liabilities
Deferred rent and other long-term liabilities		49			117
Capital leases		6			31
Warrant liabilities		41			5,307
Total Liabilities		5,562			28,432

Stockholders' equity/(deficit)
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock, $0.0001 par value; 500,000,000 shares authorized; 15,889,171 and 9,214,743 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively		2			1
Additional paid-in-capital		293,945			254,390
Accumulated deficit		(290,643	)		(279,719	)
Total Stockholders' Equity/(Deficit)		3,304			(25,328	)
Total Liabilities and Stockholders' Equity/(Deficit)	$	8,866		$	3,104

* The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017

See accompanying notes to the financial statements.

CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	Three Months Ended						Nine Months Ended
(In thousands, except per share amounts)	September 30,						September 30,
	2017			2016			2017			2016
Revenues
Healthcare services revenues	$	1,195		$	1,336		$	4,682		$	3,287

Operating expenses
Cost of healthcare services		1,664			1,253			4,361			3,381
General and administrative		2,575			2,195			8,144			6,518
Depreciation and amortization		47			38			131			102
Total operating expenses		4,286			3,486			12,636			10,001

Loss from operations		(3,091	)		(2,150	)		(7,954	)		(6,714	)

Other income		16			15			44			90
Interest expense		(1	)		(3,215	)		(3,408	)		(4,139	)
Loss on conversion of note		-			-			(1,356	)		-
Loss on issuance of common stock		-			-			(145	)		-
Change in fair value of derivative liability		-			(3,484	)		132			(6,328	)
Change in fair value of warrant liability		(2	)		1,423			1,767			673
Loss from operations before provision for income taxes		(3,078	)		(7,411	)		(10,920	)		(16,418	)
Provision for income taxes		2			2			4			7
Net Loss	$	(3,080	)	$	(7,413	)	$	(10,924	)	$	(16,425	)


Basic and diluted net loss from operations per share:	$	(0.19	)	$	(0.81	)	$	(0.84	)	$	(1.79	)

Basic weighted number of shares outstanding		15,889			9,174			13,031			9,170

*The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017.

See accompanying notes to the financial statements.

CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(unaudited)

	Nine Months Ended
(In thousands)	September 30,
	2017			2016
Operating activities:
Net loss	$	(10,924	)	$	(16,425	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		131			102
Amortization of debt discount and issuance costs included in interest expense		3,335			3,673
Provision for doubtful accounts		307			46
Deferred rent		(60	)		(52	)
Share-based compensation expense		191			523
Common stock issued for services		181			-
Loss on conversion of convertible debenture		1,356			-
Loss on issuance of common stock		145			-
Fair value adjustment on warrant liability		(1,767	)		(673	)
Fair value adjustment on derivative liability		(132	)		6,328
Changes in current assets and liabilities:
Receivables		36			(345	)
Prepaids and other current assets		113			270
Deferred revenue		1,655			1,548
Accounts payable and other accrued liabilities		85			554
Net cash used by operating activities	$	(5,348	)	$	(4,451	)

Investing activities:
Purchases of property and equipment	$	(274	)	$	(102	)
Deposits and other assets		-			16
Net cash used by investing activities	$	(274	)	$	(86	)

Financing activities:
Proceeds from the issuance of common stock and warrants	$	16,458		$	-
Proceeds from issuance of bridge loan		1,300			-
Payments on convertible debenture		(4,363	)		-
Proceeds from issuance of senior promissory note, related party		-			5,505
Proceeds from advance from related party		-			225
Payment on advance from related party		-			(225	)
Transactions costs		(1,667	)		-
Capital lease obligations		(31	)		(41	)
Net cash provided by financing activities	$	11,697		$	5,464

Net increase in cash and cash equivalents	$	6,075		$	927
Cash and cash equivalents at beginning of period		851			916
Cash and cash equivalents at end of period	$	6,926		$	1,843

Supplemental disclosure of cash paid
Interest	$	-		$	-
Income taxes	$	40		$	46
Supplemental disclosure of non-cash activity
Common stock issued for services	$	181			-
Common stock issued for conversion of debt and accrued interest	$	7,163			-
Common stock issued upon settlement of deferred compensation to officer	$	1,122			-
Common stock issued for exercise of warrants	$	-		$	45
Property and equipment acquired through capital leases and other financing	$	-		$	34

See accompanying notes to the financial statements.

Catasys, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1. Basis of Consolidation and Presentation

The accompanying unaudited condensed consolidated financial statements for Catasys, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto included in our most recent Annual Report on Form 10-K for the year-ended December 31, 2016, from which the balance sheet, as of December 31, 2016, have been derived.

Note 2. Summary of Significant Accounting Policies

Revenue Recognition

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts may include a minimum performance guarantee; we reserve a portion of the fees that may be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are not subject to the performance guarantees, we recognize the case rate ratably over the twelve months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.

Cost of Services

Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists and other staff directly involved in member care, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Salaries and fees charged by our third party administrators for processing claims are expensed when incurred and healthcare provider claims payments are recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOnTrak^TMdatabase within the contracted timeframe, with all required billing elements correctly completed by the service provider.

Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of September 30, 2017, we had $6.8 million in cash and cash equivalents exceeding federally insured limits.

For the nine months ended September 30, 2017, three customers accounted for approximately 90% of the Company’s revenues and five customers accounted for approximately 96% of accounts receivable.

Basic and Diluted Income (Loss) per Share

Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock and dilutive common equivalent shares outstanding during the period.

Common equivalent shares, consisting of 2,255,381 and 1,178,821 shares for the nine months ended September 30, 2017 and 2016, respectively, issuable upon the exercise of stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

Share-Based Compensation

Our 2017 Stock Incentive Plan (the “2017 Plan”), provides for the issuance of up to 2,333,334 shares of our common stock and an additional 243,853 shares of our common stock that are represented by awards granted under our 2010 Stock Incentive Plan (the “2010 Plan”). Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than ten years from the date of grant and employee and board of director awards generally vest over three to five years. At September 30, 2017, we had 243,853 vested and unvested shares outstanding and 2,333,334 shares available for future awards under the 2017 Plan.

Share-based compensation expense attributable to continuing operations were $32,000 and $191,000 for the three and nine months ended September 30, 2017, compared with $174,000 and $523,000 for the same periods in 2016, respectively.

Stock Options – Employees and Directors

We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.

Share-based compensation expense recognized for employees and directors for the three and nine months ended September 30, 2017 was $32,000 and $191,000, compared with $174,000 and $523,000, for the same periods in 2016, respectively.

For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our consolidated statements of operations for the three and nine months ended September 30, 2017 and 2016 is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

There were no options granted to employees and directors during the three and nine months ended September 30, 2017 and 2016, respectively, under the 2017 Plan. Employee and director stock option activity for the three and nine months ended September 30, 2017 are as follows:

				Weighted Avg.
	Shares			Exercise Price
Balance December 31, 2016		244,046		$	39.06

Granted		-		$	-
Cancelled		(193	)	$	(245.47	)

Balance March 31, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance June 30, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance September 30, 2017		243,853		$	38.90

The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the three and nine months ended September 30, 2017 and 2016, reflects the application of the simplified method prescribed in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 107 (as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of September 30, 2017, there was $127,500 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2017 Plan. That cost is expected to be recognized over a weighted-average period of approximately 1.02 years.

Stock Options and Warrants – Non-employees

We account for the issuance of options and warrants for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.

For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.

There were no options issued to non-employees for the three and nine months ended September 30, 2017 or during the same periods in 2016.

There was no share based compensation expense relating to stock options and warrants recognized for the non-employees for the three and nine months ended September 30, 2017 or during the same periods in 2016.

Common Stock

In April 2017, we entered into an underwriting agreement with Joseph Gunnar & Co., LLC (“Joseph Gunnar”), as underwriter in connection with a public offering of the Company’s securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate 3,125,000 shares of common stock at a public offering price of $4.80 per share, and the purchase price to the underwriter after discounts and commission was $4.464 per share. The closing of the offering occurred on April 28, 2017. We received $15.0 million in gross proceeds in connection with the offering.

Pursuant to the underwriting agreement with Joseph Gunnar, we granted the underwriters a 45 day over-allotment option to purchase up to 468,750 additional shares of common stock at the public offering price less the applicable underwriter discount. In May, the underwriter acquired an additional 303,750 shares pursuant to such over-allotment option. We received $1.5 million in gross proceeds in connection with the over-allotment option.

In connection with the public offering, our common stock began trading on the NASDAQ Capital Market (“NASDAQ”) under the symbol “CATS” beginning on April 26, 2017.

In April 2017, several investors, including Acuitas Group Holdings, LLC (“Acuitas”), one hundred percent (100%) of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and Shamus, LLC (“Shamus”), a Company owned by David E. Smith, a member of our board of directors, exercised their option to convert their convertible debentures and received 2,982,994 shares of common stock. There was a loss on the conversion of the convertible debentures of $1.4 million for the nine months ended September 30, 2017.

In April 2017, Terren S. Peizer agreed to settle his deferred salary balance of $1.1 million for 233,734 shares of common stock. As a result, we recognized a loss on settlement of liability totaling $83,807 which is recorded to loss on issuance of common stock.

In April 2017, we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a 1-for-6 reverse stock split of our common stock, pursuant to which each six shares of issued and outstanding common stock converted into one share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. No fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares.

All stock options and warrants to purchase common stock outstanding and our common stock reserved for issuance under our equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by six and, as applicable, multiplying the exercise price by six as a result of the reverse stock split.

There were 0 and 28,985 shares of common stock issued in exchange for investor relations services during the three and nine months ended September 30, 2017 and no common stock issued in exchange for investor relations services during the same period in 2016. Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods.

Income Taxes

We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of September 30, 2017. As such, we have not recorded a provision for income tax for the period ended September 30, 2017. We utilize the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended September 30, 2017 should be realized.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:

Level Input:		Input Definition:
Level I		Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II		Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III		Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at September 30, 2017 for assets and liabilities measured at fair value:

	Balance at September 30, 2017


(Amounts in thousands)	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		41		41
Total liabilities		-		-		41		41

Financial instruments classified as Level III in the fair value hierarchy as of September 30, 2017, represent our liabilities measured at market value on a recurring basis which include warrant liabilities resulting from recent debt financing. In accordance with current accounting rules, the warrant liabilities with anti-dilution protection are being marked-to-market each quarter-end until they are completely settled or expire. The warrants are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See Warrant Liabilities below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the three and nine months ended September 30, 2017:

	Level III				Level III
	Warrant				Derivative
(Dollars in thousands)	Liabilities			(Dollars in thousands)	Liabilities
Balance as of December 31, 2016	$	5,307		Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405		Issuance of convertible debentures		-
Change in fair value		5,181		Change in fair value		10,596
Balance as of March 31, 2017	$	12,893		Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		269		Issuance of convertible debentures		-
Change in fair value		(6,950	)	Change in fair value		(10,728	)
Write off of warrants		(6,174	)	Write off of derivative liability		(7,990	)
Balance as of June 30, 2017	$	38		Balance as of June 30, 2017	$	-

Issuance (exercise) of warrants, net		-		Issuance of convertible debentures		-
Expiration of warrants		-		Expiration of warrants		-
Change in fair value		2		Change in fair value		-
Balance as of September 30, 2017	$	40		Balance as of September 30, 2017	$	-

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years.

Warrant Liabilities

In March 2017, we entered into amendments with the holders of certain outstanding warrants issued on April 17, 2015 and July 30, 2015 to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of $5.3 million on our balance sheet as of December 31, 2016. Such amendments were contingent upon and did not take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of 11,049 shares of common stock, did not agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor, who received additional warrants to purchase 31,167 and 13,258 shares of our common stock. In addition, several warrant agreements that had anti-dilution protection had a provision in the agreement that upon an up-listing to NASDAQ, the anti-dilution protection would be removed. The up-listing to NASDAQ occurred on April 26, 2017. The elimination of the anti-dilution provision resulted in the write-off of $6.2 million of the warrant liability as of September 30, 2017.

In January 2017, we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which we received aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 (the “January 2017 Convertible Debenture”) and (ii) five-year warrants to purchase shares of our common stock in an amount equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the “January 2017 Warrants”). In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the January 2017 Convertible Debenture to April 30, 2017 or until we completes a public offering, whichever came first. In April 2017, we used the net proceeds from the public offering to repay the Loan Amount including interest of $1.3 million.

The January 2017 Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the January 2017 Warrants will be adjusted if we issue shares of our common stock at a price that is less than the then exercise price of the January 2017 Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the January 2017 Warrants, (ii) such time as the January 2017 Warrants are exercised or (iii) contemporaneously with the listing of our shares of common stock on a registered national securities exchange.

In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 14,706 shares of the Company’s common stock.

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:

	September 30, 2017
Expected volatility		93.56	%
Risk-free interest rate		1.62	%
Weighted average expected lives in years		2.54
Expected dividend		0	%

We have issued warrants to purchase common stock in February 2012, April 2015, July 2015, August 2016, December 2016, January 2017, February 2017, March 2017, April 2017, and June 2017. Some of the warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

For the three and nine months ended September 30, 2017, we recognized a loss of $2,000 and a gain of $1.8 million, respectively, compared with a gain of $1.4 million and $673,000 for the same periods in 2016, respectively, related to the revaluation of our warrant liabilities.

Derivative Liability

In July 2015, we entered into a $3.55 million 12% Original Issue Discount Convertible Debenture due January 18, 2016 with Acuitas (the “July 2015 Convertible Debenture”). The conversion price of the July 2015 Convertible Debenture is $11.40 per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be. In October 2016, we entered into an amendment of the July 2015 Convertible Debenture which extended the maturity date of the Convertible Debenture from January 18, 2016 to January 18, 2017. In addition, the conversion price of the July 2015 Convertible Debenture was subsequently adjusted to $1.80 per share. The July 2015 Convertible Debentures are unsecured, bear interest at a rate of 12% per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and are subject to mandatory prepayment upon the consummation of certain future financings. Acuitas agreed to extend the maturity date of the July 2015 Convertible Debenture to April 30, 2017 or until we completed a public offering, whichever came first. In April 2017, the July 2015 Convertible Debenture was converted into 2,385,111 shares of common stock and the derivative liability was written off.

For the three and nine months ended September 30, 2017, we recognized a gain of $0 and $132,000, respectively, compared with a loss of $3.5 million and $6.3 million for the same periods in 2016, related to the revaluation of our derivative liability.

Recently Issued or Newly Adopted Accounting Standards

In April 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-10, Revenue from Contracts with Customers (Topic 606) (“ASU 2016-10”), which amends certain aspects of the Board’s new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. We are currently evaluating the potential impact of this standard on our consolidated financial statements, as well as the available transition methods. We are currently assessing whether the adoption of ASU 2016-10 will have a material effect on our consolidated financial position or results of operations.

In March 2016, the FASB issued ASU 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The standard is effective beginning December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. The adoption of ASU 2016-09 did not have a material effect on our consolidated financial position or results of operations.

Note 3. Related Party Disclosure

In January 2017, we entered into the Subscription Agreement with Acuitas pursuant to which we received aggregate gross proceeds of $1.3 million and warrants to purchase 254,904 shares of common stock. In April 2017, we used the net proceeds from the public offering to repay the Loan Amount including interest of $1.3 million.

In January 2017, in connection with the Subscription Agreement described above, the number of Acuitas warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 137,883 shares of our common stock.

In March 2017, we entered into an amendment with Acuitas of certain outstanding warrants issued in July 2015 to eliminate certain anti-dilution provisions in such warrants. Such amendment was contingent upon and did not take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Acuitas received additional warrants to purchase 31,167 shares of our common stock in April 2017.

In April 2017, Acuitas purchased 181,154 shares of common stock for $869,539 in proceeds in connection with the public offering.

In April 2017, Acuitas converted its July 2015 convertible debenture totaling $4.3 million of principal and interest into 2,385,111 shares of common stock.

In April 2017, we used net proceeds from the public offering to repay Acuitas the December 2016 8% convertible debenture with accrued interest of $2.9 million.

In April 2017, Terren S. Peizer agreed to settle his deferred salary balance of $1.1 million for 233,734 shares of common stock, resulting in a loss on settlement of liability totaling $83,807 recorded to loss on issuance of common stock.

In addition, we have accounts payable outstanding with Mr. Peizer for travel and expenses of approximately $223,000 as of September 30, 2017.

In January 2017, in connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 14,706 shares of our common stock.

In March 2017, Shamus converted $1.3 million of their December 2016 Convertible Debentures and accrued interest for 276,204 shares of our common stock.

Note 4. Short-term Debt

In January 2017, we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which we received aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 (the “January 2017 Convertible Debenture”) and (ii) 254,904 five-year warrants to purchase shares of the Company’s common stock which is equal to one hundred percent (100%) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the “January 2017 Warrants”). In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the January 2017 Convertible Debenture to April 30, 2017 or until we completed a public offering, whichever came first. In April 2017, we used the net proceeds from the public offering to repay the Loan Amount including interest of $1.3 million.

Note 5. Restatement of Financial Statements

The prior year financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements, including the related notes, and the other financial information included elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this report and our annual report filed on Form 10-K for the year ended December 31, 2016.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING INFORMATION

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management, markets for our stock and other matters. Statements in this report that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Exchange Act of 1934, as amended (the “Exchange Act”) and Section 27A of the Securities Act of 1933, as amended. Such forward-looking statements, including, without limitation, those relating to the future business prospects, our revenue and income, wherever they occur, are necessarily estimates reflecting the best judgment of our senior management as of the date on which they were made, or if no date is stated, as of the date of this report. These forward-looking statements are subject to risks, uncertainties and assumptions, including those described in the “Risk Factors” in Item 1A of Part I of our most recent Annual Report on Form 10-K (“Form 10-K”) for the fiscal year ended December 31, 2016 and other reports we filed with the Securities and Exchange Commission (“SEC”), that may affect the operations, performance, development and results of our business. Because the factors discussed in this report could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any such forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We assume no obligation and do not intend to update these forward looking statements, except as required by law.

OVERVIEW

General

We provide big data based analytics and predictive modeling driven behavioral healthcare services to health plans through our OnTrak solution. Our OnTrak solution is designed to improve member health and at the same time lower costs to the insurer for underserved populations where behavioral health conditions are causing or exacerbating co-existing medical conditions. The program utilizes proprietary analytics and proprietary enrollment, engagement and behavioral modification capabilities to assist members who otherwise do not seek care through a patient centric treatment that integrates evidence-based medical and psychosocial interventions along with care coaching in a 52-week outpatient solution. Our initial focus was members with substance use disorders, but we have expanded our solution to assist members with anxiety and depression. We currently operate our OnTrak solutions in Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin. We provide services to commercial (employer funded), managed Medicare Advantage, and managed Medicaid and duel eligible (Medicare and Medicaid) populations.

Recent Developments

Amendments to Outstanding Warrants and Extension of Existing Debentures

In March 2017, we entered into amendments with the holders of certain outstanding warrants issued on April 17, 2015 and July 30, 2015 to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of $5.3 million on our balance sheet as of December 31, 2016. Such amendments were contingent upon and did not take effect until the closing of the public offering described below. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of 11,049 shares of common stock, did not agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor, who received additional warrants to purchase 31,167 and 13,258 shares of our common stock. In addition, several warrant agreements that had anti-dilution protection had a provision in the agreement that upon an up-listing to NASDAQ, the anti-dilution protection would be removed. The up-listing to NASDAQ occurred on April 26, 2017. The elimination of the anti-dilution provision resulted in the write-off of $6.9 million of the warrant liability as of September 30, 2017.

Reverse Stock Split

On April 21, 2017, we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware implementing a 1-for-6 reverse stock split of the Company's common stock, pursuant to which each 6 shares of issued and outstanding common stock converted into 1 share of common stock. Proportionate voting rights and other rights of common stock holders were not affected by the reverse stock split. No fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares. The 1-for-6 reverse stock split became effective at 5:00 p.m., Eastern Time, on April 24, 2017, and our common stock began trading on the OTCQB Marketplace on a post-split basis at the open of trading on April 25, 2017. Our post-reverse split common stock has a new CUSIP number: 149049 504. Other terms of the common stock were not affected by the reverse stock split. The common stock will continue to trade under the symbol "CATS."

Public Offering

On April 25, 2017, we entered into an underwriting agreement with Joseph Gunnar & Co., LLC (“Joseph Gunnar”), as underwriter in connection with a public offering of our securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate of 3,125,000 shares of common stock at a public offering price of $4.80 per share, and the purchase price to the underwriter after discounts and commissions was $4.464 per share. The closing of the offering occurred on April 28, 2017.

Pursuant to the underwriting agreement, we issued to the underwriter a warrant for the purchase of an aggregate of 156,250 shares of common stock for an aggregate purchase price of $100. The exercise price of the warrant is equal to 125% of the public offering price in the offering, or $6.00 per share of common stock.

NASDAQ Uplisting

In connection with the public offering, our common stock began trading on the Nasdaq Capital Market under the symbol “CATS” beginning on April 26, 2017.

Exercise of Over-Allotment Option

Pursuant to the underwriting with Joseph Gunnar dated April 25, 2017, we granted the underwriters a 45-day over-allotment option to purchase up to 468,750 additional shares of common stock at the public offering price less the applicable underwriter discount. On May 2, 2017, the underwriter acquired an additional 303,750 shares pursuant to such over-allotment option.

Operations

We currently operate our OnTrak solutions in Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia and Wisconsin. We provide services to commercial (employer funded), managed Medicare Advantage, and managed Medicaid and duel eligible (Medicare and Medicaid) populations. We have generated fees from our launched programs and expect to launch additional customers and increase enrollment and fees throughout 2017. However, there can be no assurance that we will generate such fees or that new programs will launch as we expect.

RESULTS OF OPERATIONS

Table of Summary Consolidated Financial Information

The table below and the discussion that follows summarize our results of consolidated operations for the three and nine months ended September 30, 2017 compared to the three and nine months ended September 30, 2016:

	Three Months Ended						Nine Months Ended
(In thousands, except per share amounts)	September 30,						September 30,
	2017			2016			2017			2016
Revenues
Healthcare services revenues	$	1,195		$	1,336		$	4,682		$	3,287

Operating expenses
Cost of healthcare services		1,664			1,253			4,361			3,381
General and administrative		2,575			2,195			8,144			6,518
Depreciation and amortization		47			38			131			102
Total operating expenses		4,286			3,486			12,636			10,001

Loss from operations		(3,091	)		(2,150	)		(7,954	)		(6,714	)

Other income		16			15			44			90
Interest expense		(1	)		(3,215	)		(3,408	)		(4,139	)
Loss on conversion of note		-			-			(1,356	)		-
Loss on issuance of common stock		-			-			(145	)		-
Change in fair value of derivative liability		-			(3,484	)		132			(6,328	)
Change in fair value of warrant liability		(2	)		1,423			1,767			673
Loss from operations before provision for income taxes		(3,078	)		(7,411	)		(10,920	)		(16,418	)
Provision for income taxes		2			2			4			7
Net Loss	$	(3,080	)	$	(7,413	)	$	(10,924	)	$	(16,425	)

Summary of Consolidated Operating Results

Loss from operations before provision for income taxes for the three and nine months ended September 30, 2017 was $3.1 million and $10.9 million, compared with a net loss of $7.4 million and $16.4 million for the same periods in 2016, respectively. The difference primarily relates to the change in fair value of warrant liability and derivative liability for the three and nine months ended September 30, 2017, compared to the same periods in 2016.

Revenues

During the nine months ended September 30, 2017, we have expanded OnTrak for one customer into two new lines of business, another customer expanded into their largest state by membership, and launched enrollment with a new health plan in Oklahoma. In addition, at the end of the second quarter 2017 we saw a significant increase in our eligible member population as a result of another customer with programs in eight states resolving a previous data extraction issue. That increase in eligible membership is expected to primarily impact future quarters. These expansions were offset to some extent by two customers exiting certain health exchange and Medicaid markets, and one customer suspending new enrollments. Overall, there was a net increase in the number of patients enrolled in our solutions compared with the same period in 2016. Enrolled members as of September 30, 2017 was 33% greater than September 30, 2016. Recognized revenue decreased by $141,000 and increased by $1.4 million, or (11)% and 42%, for the three and nine months ended September 30, 2017, compared with the same periods in 2016, respectively. We reserve a portion, and in some cases all, of the fees we receive related to enrolled members, as the fees are subject to performance guarantees or are received as case rates in advance at the time of enrollment. Fees deferred for performance guarantees are recognized when those guarantees are satisfied and fees received in advance are recognized ratably over the period of enrollment. Deferred revenue increased by $1.7 million from December 31, 2016.

Cost of Healthcare Services

Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists, healthcare provider claims payments to our network of physicians and psychologists, and fees charged by our third party administrators for processing these claims. The increase of $411,000 and $979,000 for the three and nine months ended September 30, 2017, compared with the same periods in 2016, respectively, relates primarily to the increase in members being treated, the addition of care coaches, outreach specialists, community care coordinators and other staff to manage the increasing number of enrolled members. In addition, we hire staff in preparation for anticipated future customer contracts and corresponding increases in members eligible for OnTrak. The costs for such staff are included in Cost of Healthcare Services during training and ramp-up periods.

General and Administrative Expenses

Total general and administrative expense increased by $379,000 and $1.6 million for the three and nine months ended September 30, 2017, compared with the same periods in 2016. The increase was due primarily to an increase in salaries to service our contracts and increasing number of enrolled members, investments in key personnel to support future growth, and investor relations services during the nine months ended September 30, 2017.

Depreciation and Amortization

Depreciation and amortization was immaterial for the three and nine months ended September 30, 2017 and 2016, respectively.

Interest Expense

Interest expense decreased by $3.2 million and $731,000 for the three and nine months ended September 30, 2017, respectively, compared with the same periods in 2016. The decrease is primarily related to the value of the warrants issued during the third quarter of 2016 for the 2016 Convertible Debentures as well as the amortization of the debt discount on the 2016 Convertible Debentures. No such issuance occurred during the third quarter of 2017.

Loss of conversion of note

Loss on conversion of note during the three and nine months ended September 30, 2017 relates to the conversion of the July 2015 convertible debenture and a portion of the December 2016 convertible debentures. No such conversion occurred during 2016.

Loss on issuance of common stock

Loss on the issuance of common stock relates to the issuance of common stock to Acuitas in the public offering and to pay Terren Peizer’s deferred salary.

Change in fair value of warrant liability

The change in fair value for the warrants was $1.4 million and $1.1 million for the three and nine months ended September 30, 2017, respectively, compared with the same periods in 2016, respectively.

In April 2017, we removed the anti-dilution protection in most of our warrants. We will continue to mark-to-market the remaining warrants with anti-dilution protection to market value each quarter-end until they are completely settled or expire.

Change in fair value of derivative liability

The change in fair value of derivative liabilities was $3.5 million and $6.2 million for the three and nine months ended September 30, 2017, respectively, compared with the same periods in 2016. The derivative liability was the result of the issuance of the July 2015 Convertible Debenture, which was converted into 2,385,111 shares of common stock in April 2017.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

As of November 13, 2017, we had a balance of approximately $5.9 million cash on hand. We had working capital of approximately $2.5 million as of September 30, 2017. We have incurred significant operating losses and negative operating cash flows since our inception. We could continue to incur negative cash flows and operating losses for the next twelve months. Our current cash burn rate is approximately $588,000 per month, excluding non-current accrued liability payments. In April 2017, we closed on a public offering for aggregate gross proceeds of $16.5 million prior to deducting underwriter discounts, commission and other estimated offering expenses. We expect our current cash resources to cover expenses through at least the next twelve months, however, delays in cash collections, revenue, or unforeseen expenditures could impact this estimate.

Cash Flows

We used $5.3 million of cash for operating activities during the nine months ended September 30, 2017 compared with $4.5 million in the same period in 2016. The increase in cash used in operating activities reflects the increase in the number of members being treated, the addition of care coaches and clinical care coordinators to our staff to manage the increasing number of enrolled members, the expansion of our program for one customer into two new lines of business, another customer expanding into their largest state by membership, and the launch of a new health plan in Oklahoma. In addition, at the end of the second quarter 2017 we saw a significant increase in our eligible member population as a result of another customer with programs in either states resolving a previous data extraction issue. Significant non-cash adjustments to operating activities for the nine months ended September 30, 2017 included a loss on conversion of convertible debentures of $1.4 million, a fair value adjustment on warrant liability of $1.8 million, and amortization of debt discount and issuance costs of $3.3 million related to the January 2017 convertible debenture.

Capital expenditures for the nine months ended September 30, 2017 were not material. We anticipate that capital expenditures will increase in the future as we replace our computer systems that are reaching their useful lives, upgrade equipment to support our increased number of enrolled members, and enhance the reliability and security of our systems. These future capital expenditure requirements will depend upon many factors, including obsolescence or failure of our systems, progress with expanding the adoption of our solutions, and our marketing efforts, the necessity of, and time and costs involved in obtaining, regulatory approvals, competing technological and market developments, and our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements.

Our net cash provided by financing activities was $11.7 million for the nine months ended September 30, 2017, compared with net cash provided by financing activities of $5.5 million for the nine months ended September 30, 2016, respectively. Cash provided by financing activities for the nine months ended September 30, 2017 consisted of the gross proceeds from the issuance of common stock from the public offering of $16.5 million, the gross proceeds from the convertible debenture provided by Acuitas Group Holdings, LLC (“Acuitas”), one hundred percent (100%) of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, in January 2017 of $1.3 million, offset by transaction costs of $1.7 million for the public offering and the payment of convertible debentures of $4.4 million leaving a balance of $6.9 million in cash and cash equivalents at September 30, 2017.

As discussed above, we currently expend cash at a rate of approximately $588,000 per month. We also anticipate cash inflow to increase during 2017 as we continue to service our executed contracts and sign new contracts. We expect our current cash resources to cover our operations through at least the next twelve months, however, delays in cash collections, revenue, or unforeseen expenditures could impact this estimate.

OFF BALANCE SHEET ARRANGEMENTS

As of September 30, 2017, we had no off-balance sheet arrangements.

CRITICAL ACCOUNTING ESTIMATES

The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. We base our estimates on experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that may not be readily apparent from other sources. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. Our actual results may differ from these estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different results when using different assumptions. We have discussed these critical accounting estimates, the basis for their underlying assumptions and estimates and the nature of our related disclosures herein with the audit committee of our Board of Directors. We believe our accounting policies related to the fair value of warrants, the estimation of the fair value of our derivative liabilities, and share-based compensation expense, involve our most significant judgments and estimates that are material to our consolidated financial statements. They are discussed further below.

Warrant Liabilities

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions:

	September 30, 2017
Expected volatility		93.56	%
Risk-free interest rate		1.62	%
Weighted average expected lives in years		2.54
Expected dividend		0	%

Derivative Liabilities

In July 2015, we entered into a $3.55 million 12% Original Issue Discount Convertible Debenture due January 18, 2016 with Acuitas (the “July 2015 Convertible Debenture”). The conversion price of the July 2015 Convertible Debenture is $11.40 per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be. In October 2016, we entered into an amendment of the July 2015 Convertible Debenture which extended the maturity date of the Convertible Debenture from January 18, 2016 to January 18, 2017. In addition, the conversion price of the July 2015 Convertible Debenture was subsequently adjusted to $1.80 per share. The July 2015 Convertible Debentures are unsecured, bear interest at a rate of 12% per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and are subject to mandatory prepayment upon the consummation of certain future financings. Acuitas agreed to extend the maturity date of the July 2015 Convertible Debenture to April 30, 2017 or until we completed a public offering, whichever comes first. In April 2017, the July 2015 Convertible Debenture was converted into 2,385,111 shares of common stock and the derivative liability was written off.

Share-based compensation expense

We account for the issuance of stock, stock options, and warrants for services from non-employees based on an estimate of the fair value of options and warrants issued using the Black-Scholes pricing model. This model’s calculations include the exercise price, the market price of shares on grant date, weighted average assumptions for risk-free interest rates, expected life of the option or warrant, expected volatility of our stock and expected dividend yield.

The amounts recorded in the financial statements for share-based compensation expense could vary significantly if we were to use different assumptions. For example, the assumptions we have made for the expected volatility of our stock price have been based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. If we were to use a different volatility than the actual volatility of our stock price, there may be a significant variance in the amounts of share-based compensation expense from the amounts reported. The weighted average expected option term for the nine months ended September 30, 2017 and 2016, reflects the application of the simplified method set out in SEC Staff Accounting Bulletin No. 107, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

From time to time, we retain terminated employees as part-time consultants upon their resignation from the Company. Because the employees continue to provide services to us, their options continue to vest in accordance with the original terms. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards and are accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. There were no employees moved to consulting status for the three and nine months ended September 30, 2017 and 2016.

RECENT ACCOUNTING PRONOUNCEMENTS

In April 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-10, Revenue from Contracts with Customers (Topic 606) (“ASU 2016-10”), which amends certain aspects of the Board’s new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the potential impact of this standard on our consolidated financial statements, as well as the available transition methods. We are currently assessing whether the adoption of ASU 2016-10 will have a material effect on our consolidated financial position or results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Disclosure Controls

We have evaluated, with the participation of our principal executive officer and our principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2017. Based on this evaluation, our principal executive officer and our principal financial officer have concluded that, as of September 30, 2017, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the three months ended September 30, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit 31.1*		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2*		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1**		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2**		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance
101.SCH*		XBRL Taxonomy Extension Schema
101.CAL*		XBRL Taxonomy Extension Calculation
101.DEF*		XBRL Taxonomy Extension Definition
101.LAB*		XBRL Taxonomy Extension Labels
101.PRE*		XBRL Taxonomy Extension Presentation

* filed herewith.

** furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CATASYS, INC.


Date: November 14, 2017	By:	/s/ TERREN S. PEIZER
		Terren S. Peizer
		Chief Executive Officer (Principal Executive Officer)


Date: November 14, 2017	By:	/s/ CHRISTOPHER SHIRLEY
		Christopher Shirley
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex_99633.htm EXHIBIT 31.1 ex_99633.htm

Exhibit 31.1

CERTIFICATION

I, Terren S. Peizer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2017	/s/ TERREN S. PEIZER
	Terren S. Peizer
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 ex_99634.htm EXHIBIT 31.2 ex_99634.htm

Exhibit 31.2

CERTIFICATION

I, Christopher Shirley, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2017	/s/ CHRISTOPHER SHIRLEY
	Christopher Shirley
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 ex_99635.htm EXHIBIT 32.1 ex_99635.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the “Company) for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report), I, Terren S. Peizer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ TERREN S. PEIZER		November 14, 2017
Terren S. Peizer		Date
Chief Executive Officer
(Principal Executive Officer)

EX-32.2 5 ex_99636.htm EXHIBIT 32.2 ex_99636.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the “Company) for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report), I, Christopher Shirley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ CHRISTOPHER SHIRLEY		November 14, 2017
Christopher Shirley		Date
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-101.INS 6 cats-20170930.xml XBRL INSTANCE DOCUMENT 468750 0.25 254904 0.2 1 0.75 1 0.75 1 0.25 45000 233734 1100000 6174000 7990000 -1400000 -1356000 -83807 -145000 3 5 225000 225000 4.464 5300000 41000 5307000 41000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Warrant Liabilities</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2017, </div>we entered into amendments with the holders of certain outstanding warrants issued on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 17, 2015 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 30, 2015 </div>to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.3</div> million on our balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016. </div>Such amendments were contingent upon and did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.2</div> shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,049</div> shares of common stock, did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor, who received additional<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,167</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,258</div> shares of our common stock. In addition, several warrant agreements that had anti-dilution protection had a provision in the agreement that upon an up-listing to NASDAQ, the anti-dilution protection would be removed. The up-listing to NASDAQ occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 26, 2017. </div>The elimination of the anti-dilution provision resulted in the write-off of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million of the warrant liability as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017.</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">        In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which we receive<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">d aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,300,000</div> (the “Loan Amount”) in consideration of the issuance of (i) an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> Series B Convertible Debenture due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 (</div>the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January 2017 </div>Convertible Debenture”) and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year warrants to purchase shares of our common stock in an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one hundred</div> percent (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div>) of the initial number of shares of common stock issuable upon the conversion of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Convertible Debenture, at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.10</div> per share (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January 2017 </div>Warrants”). In addition, any warrants issued in conjunction with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016 </div>Convertible Debenture currently outstanding with Acuitas have been increased by an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137,883</div> shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Convertible Debenture to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 30, 2017 </div>or until we completes a public offering, whichever came first. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>we used the net proceeds from the public offering to repay the Loan Amount including interest of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">      The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants will be adjusted if we issue shares of our common stock at a price that is less than the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants, (ii) such time as the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants are exercised or (iii) contemporaneously with the listing of our shares of common stock on a registered national securities exchange.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">      In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016 </div>Convertible Debenture were increased from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,706</div> shares of the Company’s common stock.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 36pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 81%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> 30</div><div style="display: inline; font-weight: bold;">, </div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected volatility</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.56</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Weighted average expected lives in years</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected dividend</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We have issued warrants<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> to purchase common stock in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2012, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2015, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017. </div>Some of the warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Fo<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">r the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we recognized a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,000</div> and a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.8</div> million, respectively, compared with a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$673,000</div> for the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, related to the revaluation of our warrant liabilities.</div></div></div></div></div></div></div> P5Y 6200000 false --12-31 Q3 2017 2017-09-30 10-Q 0001136174 15889171 Yes Smaller Reporting Company CATASYS, INC. No No cats

806000

870000

1751000

1620000

293945000

254390000

277000

3335000

3673000

2255381

1178821

8866000

3104000

7942000

2323000

106000

6000

31000

851000

916000

6926000

1843000

106000

6075000

927000

6800000

5.10

11049

31167

13258

137883

14706

254904

137883

31167

0.0001

500000000

15889171

9214743

15889171

9214743

2000

1000

0.9

0.96

1664000

1253000

4361000

3381000

7163000

2982994

2385111

276204

4300000

1300000

11.40

1.80

3550000

0.08

0.12

0.08

216000

49000

117000

3180000

1525000

47000

38000

131000

102000

131000

102000

132000

-3500000

-6300000

8122000

223000

9796000

-0.19

-0.81

-0.84

-1.79

901000

2089000

127500

P1Y7D

2000

-1767000

-1423000

-673000

P2Y197D

0.9356

0.0162

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrant </div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Derivative </div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Dollars in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Dollars in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,405</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,181</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,596</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance (exercise) of warrants, net</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">269</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,728</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Write off of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,174</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Write off of derivative liability</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,990</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance (exercise) of warrants, net</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Expiration of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Expiration of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </table></div>

5181000

10596000

-6950000

-10728000

2000

2405000

269000

5307000

8122000

12893000

18718000

38000

40000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) an entity<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of the fair value hierarchy are described below:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><div style="display: inline; font-weight: bold;"> </div></div> <table border="0px" cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-size: 10pt; margin: 0pt auto 0pt 45pt; font-family: Times New Roman; min-width: 700px;"> <tr> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Level<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> Input:</div></div></div> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Input Definition:</div></div> </td> </tr> <tr> <td style="vertical-align: top; width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level I</div> </td> <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 1%;"> </td> <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</div> </td> </tr> <tr> <td style="vertical-align: top; width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level II</div> </td> <td style="vertical-align: top; width: 1%;"> </td> <td style="vertical-align: top; width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</div> </td> </tr> <tr> <td style="vertical-align: top; width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level III</div> </td> <td style="vertical-align: top; width: 1%;"> </td> <td style="vertical-align: top; width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unobservable inputs that reflect management<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</div></div> </td> </tr> </table> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The following table summarizes fair value measurements by level at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>for assets and liabilities measured at fair value:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:22pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 45pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Balance at September 30, 2017</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Amounts in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level I</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level II</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Certificates of deposit</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Total assets</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Warrant liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Total liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Financial instruments classified as Level <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">III in the fair value hierarchy as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>represent our liabilities measured at market value on a recurring basis which include warrant liabilities resulting from recent debt financing. In accordance with current accounting rules, the warrant liabilities with anti-dilution protection are being marked-to-market each quarter-end until they are completely settled or expire. The warrants are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See <div style="display: inline; font-style: italic;">Warrant Liabilities</div> below. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017:</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrant </div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Derivative </div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Dollars in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Dollars in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,405</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,181</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,596</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance (exercise) of warrants, net</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">269</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,728</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Write off of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,174</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Write off of derivative liability</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,990</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance (exercise) of warrants, net</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Expiration of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Expiration of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </table> </div></div></div></div></div></div>

2575000

2195000

8144000

6518000

1195000

1336000

4682000

3287000

-3078000

-7411000

-10920000

-16418000

2000

4000

7000

40000

46000

85000

554000

-36000

345000

1655000

1548000

-60000

-52000

-113000

-270000

1000

3215000

3408000

4139000

181000

5562000

28432000

8866000

3104000

5466000

22977000

41000

11697000

5464000

-274000

-86000

-5348000

-4451000

-3080000

-7413000

-10924000

-16425000

34000

4286000

3486000

12636000

10001000

-3091000

-2150000

-7954000

-6714000

579000

575000

371000

16000

15000

44000

90000

1667000

-16000

274000

102000

0.0001

50000000

307000

420000

15000000

1500000

869539

16458000

1300000

5505000

1300000

553000

410000

P2Y

P7Y

P5Y

P7Y

307000

46000

709000

1052000

1300000

2900000

4363000

31000

41000

-290643000

-279719000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 45pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Balance at September 30, 2017</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Amounts in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level I</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level II</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Certificates of deposit</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Total assets</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Warrant liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Total liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 99pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Avg.</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,046</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(193</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(245.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

32000

191000

174000

523000

32000

191000

174000

523000

191000

523000

P3Y

P5Y

2333334

243853

2333334

193

244046

243853

39.06

38.90

243853

245.47

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Stock Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2017</div> Plan”), provides for the issuance of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,333,334</div> shares of our common stock<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> and an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div> shares of our common stock that are represented by awards granted under our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Stock Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2010</div> Plan”). Incentive stock options (ISOs) under Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">422A</div> of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> later than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from the date of grant and employee and board of director awards generally vest over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div> vested and unvested shares outstanding and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,333,334</div> shares available for future awards under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">S<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">hare-based compensation expense attributable to continuing operations were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$32,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$191,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>compared with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$174,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$523,000</div> for the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Stock Options <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">– Employees and Directors</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Share-based compensation expense recognized <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">for employees and directors for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$32,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$191,000,</div> compared with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$174,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$523,000,</div> for the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> consolidated statements of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div></div></div></div></div></div></div></div></div></div>options granted to employees and directors during the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan. Employee and director stock option activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>are as follows:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 99pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Avg.</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,046</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(193</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(245.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> reflects the application of the simplified method prescribed in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107</div> (as amended by SAB <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110</div>), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">As of <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$127,500</div> of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan. That cost is expected to be recognized over a weighted-average period of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.02</div> years.</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">          </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Stock Options and Warrants <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">– Non-employees</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We account for the issuance of options and warrants<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> options issued to non-employees for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>or during the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">There was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> share based compensation expense relating to stock options and warrants recognized for the non-employees for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>or during the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div></div></div></div></div></div></div>

P10Y

4.80

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Summary of Significant Accounting Policies</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;"><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>include a minimum performance guarantee; we reserve a portion of the fees that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> subject to the performance guarantees, we recognize the case rate ratably over the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Cost of Services</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists and other staff directly involved in member care, healthcare provider claims payments, and fees charged by our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party administrators for processing these claims. Salaries and fees charged by our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party administrators for processing claims are expensed when incurred and healthcare provider claims payments are recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOn<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Trak</div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">TM </div>database within the contracted timeframe, with all required billing elements correctly completed by the service provider.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Cash Equivalents and Concentration of Credit Risk</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We consider all highly liquid investments with an original maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality financial institutions<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">. The deposited cash <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.8</div> million in cash and cash equivalents exceeding federally insured limits.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">For the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> customers accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90%</div> of the Company’s revenues and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> customers accounted for approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96%</div> of accounts receivable. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Basic and Diluted </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">Income (</div><div style="display: inline; font-weight: bold;">Loss</div><div style="display: inline; font-weight: bold;">)</div><div style="display: inline; font-weight: bold;"> per Share</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock and dilutive common equivalent shares outstanding during the period.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Common equivalent shares, consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,255,381</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,178,821</div> shares for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, issuable upon the exercise of<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Stock Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2017</div> Plan”), provides for the issuance of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,333,334</div> shares of our common stock<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> and an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div> shares of our common stock that are represented by awards granted under our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010</div> Stock Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2010</div> Plan”). Incentive stock options (ISOs) under Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">422A</div> of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> later than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years from the date of grant and employee and board of director awards generally vest over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div> vested and unvested shares outstanding and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,333,334</div> shares available for future awards under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">S<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">hare-based compensation expense attributable to continuing operations were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$32,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$191,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>compared with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$174,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$523,000</div> for the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Stock Options <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">– Employees and Directors</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Share-based compensation expense recognized <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">for employees and directors for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$32,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$191,000,</div> compared with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$174,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$523,000,</div> for the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> consolidated statements of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div></div></div></div></div></div></div></div></div></div>options granted to employees and directors during the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan. Employee and director stock option activity for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>are as follows:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 99pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Avg.</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244,046</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(193</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(245.47</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Cancelled</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 62%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:0pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> reflects the application of the simplified method prescribed in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107</div> (as amended by SAB <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110</div>), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">As of <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$127,500</div> of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan. That cost is expected to be recognized over a weighted-average period of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.02</div> years.</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">          </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Stock Options and Warrants <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">– Non-employees</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We account for the issuance of options and warrants<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> options issued to non-employees for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>or during the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">There was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> share based compensation expense relating to stock options and warrants recognized for the non-employees for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>or during the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Common Stock</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">we entered into an underwriting agreement with Joseph Gunnar & Co., LLC (“Joseph Gunnar”), as underwriter in connection with a public offering of the Company’s securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,125,000</div> shares of common stock at a public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.80</div> per share, and the purchase price to the underwriter after discounts and commission was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.464</div> per share. The closing of the offering occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 28, 2017. </div>We received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.0</div> million in gross proceeds in connection with the offering. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Pursuant to the underwriting agreement with Joseph Gunnar, we <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">granted the underwriters a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div> day over-allotment option to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">468,750</div> additional shares of common stock at the public offering price less the applicable underwriter discount. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May, </div>the underwriter acquired an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">303,750</div> shares pursuant to such over-allotment option. We received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.5</div> million in gross proceeds in connection with the over-allotment option.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In connection with the public offering, our common stock began trading on the NASDAQ Capital Market <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">(“NASDAQ”) under the symbol “CATS” beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 26, 2017.</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>several investors, including Acuitas Group Holdings, LLC (“Acuitas”), <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one hundred</div> percent (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div>) of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and Shamus, LLC (“Shamus”), a Company owned by David E. Smith, a member of our board of directors, exercised their option to convert their <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">convertible debentures and received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,982,994</div> shares of common stock. There was a loss on the conversion of the convertible debentures of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017.</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>Terren S. Peizer agreed to settle his deferred salary balance of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233,734</div> shares of common stock.<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> As a result, we recognized a loss on settlement of liability totaling <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$83,807</div> which is recorded to loss on issuance of common stock.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> reverse stock split<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> of our common stock, pursuant to which each <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> shares of issued and outstanding common stock converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock. Proportionate voting rights and other rights of common stock holders were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> affected by the reverse stock split.  <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">All stock options and warrants to purchase common stock outstanding and our common stock reserved for issuance under our equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> and, as applicable, multiplying the exercise price by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> as a result of the reverse stock split.</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">There were<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,985</div> shares of common stock issued in exchange for investor relations services during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> common stock issued in exchange for investor relations services during the same period in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Income Taxes</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We have<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017.  </div>As such, we have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recorded a provision for income tax for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017.  </div>We utilize the liability method of accounting for income taxes as set forth in ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">740,</div> Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that some of the deferred tax assets will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be realized. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> likelihood that a tax benefit will be sustained, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> tax benefit has been recognized in the financial statements.  Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>should be realized.   </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) an entity<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of the fair value hierarchy are described below:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><div style="display: inline; font-weight: bold;"> </div></div> <table border="0px" cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-size: 10pt; margin: 0pt auto 0pt 45pt; font-family: Times New Roman; min-width: 700px;"> <tr> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Level<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> Input:</div></div></div> </td> <td style="vertical-align: bottom; width: 1%;"> </td> <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Input Definition:</div></div> </td> </tr> <tr> <td style="vertical-align: top; width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level I</div> </td> <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 1%;"> </td> <td style="vertical-align: top; border-bottom: 1px none rgb(0, 0, 0); width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</div> </td> </tr> <tr> <td style="vertical-align: top; width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level II</div> </td> <td style="vertical-align: top; width: 1%;"> </td> <td style="vertical-align: top; width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</div> </td> </tr> <tr> <td style="vertical-align: top; width: 14%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level III</div> </td> <td style="vertical-align: top; width: 1%;"> </td> <td style="vertical-align: top; width: 85%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unobservable inputs that reflect management<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</div></div> </td> </tr> </table> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The following table summarizes fair value measurements by level at <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017 </div>for assets and liabilities measured at fair value:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:22pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 45pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Balance at September 30, 2017</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Amounts in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level I</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level II</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Certificates of deposit</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Total assets</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 36%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Warrant liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 36%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Total liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Financial instruments classified as Level <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">III in the fair value hierarchy as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>represent our liabilities measured at market value on a recurring basis which include warrant liabilities resulting from recent debt financing. In accordance with current accounting rules, the warrant liabilities with anti-dilution protection are being marked-to-market each quarter-end until they are completely settled or expire. The warrants are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See <div style="display: inline; font-style: italic;">Warrant Liabilities</div> below. </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017:</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level III</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrant </div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Derivative </div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Dollars in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(Dollars in thousands)</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Liabilities</div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of December 31, 2016</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,405</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,181</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,596</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,893</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of March 31, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,718</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance (exercise) of warrants, net</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">269</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,950</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,728</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Write off of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,174</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Write off of derivative liability</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,990</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of June 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 15%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance (exercise) of warrants, net</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Issuance of convertible debentures</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Expiration of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Expiration of warrants</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Change in fair value</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 32%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance as of September 30, 2017</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Property and Equipment</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">seven</div> years.</div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Warrant Liabilities</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2017, </div>we entered into amendments with the holders of certain outstanding warrants issued on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 17, 2015 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 30, 2015 </div>to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.3</div> million on our balance sheet as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2016. </div>Such amendments were contingent upon and did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">.2</div> shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,049</div> shares of common stock, did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor, who received additional<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,167</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,258</div> shares of our common stock. In addition, several warrant agreements that had anti-dilution protection had a provision in the agreement that upon an up-listing to NASDAQ, the anti-dilution protection would be removed. The up-listing to NASDAQ occurred on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 26, 2017. </div>The elimination of the anti-dilution provision resulted in the write-off of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million of the warrant liability as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017.</div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">        In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which we receive<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">d aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,300,000</div> (the “Loan Amount”) in consideration of the issuance of (i) an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> Series B Convertible Debenture due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 (</div>the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January 2017 </div>Convertible Debenture”) and (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-year warrants to purchase shares of our common stock in an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one hundred</div> percent (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div>) of the initial number of shares of common stock issuable upon the conversion of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Convertible Debenture, at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.10</div> per share (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “January 2017 </div>Warrants”). In addition, any warrants issued in conjunction with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016 </div>Convertible Debenture currently outstanding with Acuitas have been increased by an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137,883</div> shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Convertible Debenture to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 30, 2017 </div>or until we completes a public offering, whichever came first. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>we used the net proceeds from the public offering to repay the Loan Amount including interest of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">      The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants will be adjusted if we issue shares of our common stock at a price that is less than the then exercise price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants, (ii) such time as the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017 </div>Warrants are exercised or (iii) contemporaneously with the listing of our shares of common stock on a registered national securities exchange.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">      In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016 </div>Convertible Debenture were increased from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> warrant coverage, exercisable for an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,706</div> shares of the Company’s common stock.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">:</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 36pt; font-size: 10pt; font-family: Times New Roman,Times,serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman,Times,serif; font-size: 10pt; width: 81%;"> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;"> 30</div><div style="display: inline; font-weight: bold;">, </div></div></div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">7</div></div></div></div> </td> <td style="font-family: Times New Roman,Times,serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected volatility</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.56</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Weighted average expected lives in years</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected dividend</div> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">%</div> </td> </tr> </table> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">We have issued warrants<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> to purchase common stock in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2012, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2015, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2017. </div>Some of the warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Fo<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">r the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we recognized a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,000</div> and a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.8</div> million, respectively, compared with a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$673,000</div> for the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively, related to the revaluation of our warrant liabilities.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Derivative Liability</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015, </div>we entered into<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.55</div> million <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12%</div> Original Issue Discount Convertible Debenture due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 18, 2016 </div>with Acuitas (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> “July 2015 </div>Convertible Debenture”). The conversion price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015 </div>Convertible Debenture is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.40</div> per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be.  In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2016, </div>we entered into an amendment of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015 </div>Convertible Debenture which extended the maturity date of the Convertible Debenture from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 18, 2016 </div>to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 18, 2017. </div>In addition, the conversion price of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015 </div>Convertible Debenture was subsequently adjusted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.80</div> per share. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015 </div>Convertible Debentures are unsecured, bear interest at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12%</div> per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and are subject to mandatory prepayment upon the consummation of certain future financings. Acuitas agreed to extend the maturity date of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015 </div>Convertible Debenture to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 30, 2017 </div>or until we completed a public offering, whichever came first. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2015 </div>Convertible Debenture was converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,385,111</div> shares of common stock and the derivative liability was written off.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Fo<div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">r the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>we recognized a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$132,000,</div> respectively, compared with a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.5</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.3</div> million for the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> related to the revaluation of our derivative liability.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Recently Issued or Newly Adopted Accounting Standards</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2016, </div>the FASB issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> <div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"><div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>)</div><div style="display: inline; font-style: italic;"> </div>(“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10”</div>), which amends certain aspects of the Board’s new revenue standard, ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> which is effective for annual and interim periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>We are currently evaluating the potential impact of this standard on our consolidated financial statements, as well as the available transition methods. We are currently assessing whether the adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> will have a material effect on our consolidated financial position or results of operations.</div></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </div> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;"></div> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;"> <div style="display: inline; font-style: italic;">Compensation — Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>): Improvements to Employee Share-Based Payment Accounting</div><div style="display: inline; font-style: italic;"> </div>(“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09”</div>), which outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The standard is effective beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2016, </div>and interim periods within those annual periods. Early adoption is permitted. </div><div style="display: inline; font-family:Times New Roman, Times, serif;font-size:10pt;">The adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material effect on our consolidated financial position or results of operations.</div></div></div>

1122000

28985

3125000

303750

181154

3304000

-25328000

-3484000

132000

-6328000

15889000

9174000

13031000

9170000

The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017. The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001136174 2016-01-01 2016-09-30 0001136174 cats:CommonStockIssuedForInvestorRelationServicesMember 2016-01-01 2016-09-30 0001136174 cats:CommonStockIssuedForConversionOfDebtAndAccruedInterestMember 2016-01-01 2016-09-30 0001136174 cats:CommonStockIssuedUponSettlementOfDeferredCompensationToOfficerMember 2016-01-01 2016-09-30 0001136174 cats:The2017StockIncentivePlanMember 2016-01-01 2016-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:EmployeesAndDirectorsMember 2016-01-01 2016-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:NonemployeesMember 2016-01-01 2016-09-30 0001136174 2016-07-01 2016-09-30 0001136174 cats:CommonStockIssuedForInvestorRelationServicesMember 2016-07-01 2016-09-30 0001136174 cats:The2017StockIncentivePlanMember 2016-07-01 2016-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:EmployeesAndDirectorsMember 2016-07-01 2016-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:NonemployeesMember 2016-07-01 2016-09-30 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2017-01-01 2017-01-31 0001136174 cats:January2017WarrantsMember cats:AcuitasMember 2017-01-01 2017-01-31 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-01-01 2017-01-31 0001136174 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-01-01 2017-03-31 0001136174 cats:WarrantsMember 2017-01-01 2017-03-31 0001136174 cats:EmployeesAndDirectorsMember 2017-01-01 2017-03-31 0001136174 2017-01-01 2017-09-30 0001136174 cats:CommonStockIssuedForInvestorRelationServicesMember 2017-01-01 2017-09-30 0001136174 cats:AmendedWarrantsMember 2017-01-01 2017-09-30 0001136174 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-09-30 0001136174 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember cats:FiveCustomersMember 2017-01-01 2017-09-30 0001136174 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-09-30 0001136174 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cats:ThreeCustomersMember 2017-01-01 2017-09-30 0001136174 cats:SeveralInvestorsIncludingAcuitasAndShamusMember cats:ConvertibleDebenturesMember 2017-01-01 2017-09-30 0001136174 cats:CommonStockIssuedForConversionOfDebtAndAccruedInterestMember 2017-01-01 2017-09-30 0001136174 cats:WarrantLiabilityMember 2017-01-01 2017-09-30 0001136174 us-gaap:DomesticCountryMember 2017-01-01 2017-09-30 0001136174 cats:CommonStockIssuedUponSettlementOfDeferredCompensationToOfficerMember 2017-01-01 2017-09-30 0001136174 cats:ReverseStockSplitMember 2017-01-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember 2017-01-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:EmployeesAndDirectorsMember 2017-01-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:NonemployeesMember 2017-01-01 2017-09-30 0001136174 cats:FurnitureAndEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001136174 cats:FurnitureAndEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001136174 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2017-01-01 2017-09-30 0001136174 us-gaap:LeaseholdImprovementsMember us-gaap:MinimumMember 2017-01-01 2017-09-30 0001136174 cats:ShamusMember cats:ConversionOfDecember2016ConvertibleDebenturesIntoCommonStockMember 2017-03-01 2017-03-31 0001136174 cats:SeveralInvestorsIncludingAcuitasAndShamusMember cats:ConvertibleDebenturesMember 2017-04-01 2017-04-30 0001136174 cats:December2016ConvertibleDebentureMember cats:AcuitasMember 2017-04-01 2017-04-30 0001136174 cats:July2015ConvertibleDebentureMember cats:AcuitasMember 2017-04-01 2017-04-30 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-04-01 2017-04-30 0001136174 cats:AcuitasMember cats:PublicOfferingMember 2017-04-01 2017-04-30 0001136174 cats:ChairmanAndChiefExecutiveOfficerMember 2017-04-01 2017-04-30 0001136174 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-04-01 2017-06-30 0001136174 cats:WarrantsMember 2017-04-01 2017-06-30 0001136174 cats:EmployeesAndDirectorsMember 2017-04-01 2017-06-30 0001136174 cats:ReverseStockSplitMember 2017-04-25 2017-04-25 0001136174 cats:JosephGunnarAndCoLLCMember cats:PublicOfferingMember 2017-04-28 2017-04-28 0001136174 cats:JosephGunnarAndCoLLCMember us-gaap:OverAllotmentOptionMember 2017-05-01 2017-05-31 0001136174 2017-07-01 2017-09-30 0001136174 cats:CommonStockIssuedForInvestorRelationServicesMember 2017-07-01 2017-09-30 0001136174 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-07-01 2017-09-30 0001136174 cats:WarrantsMember 2017-07-01 2017-09-30 0001136174 cats:ReverseStockSplitMember 2017-07-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember 2017-07-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:EmployeesAndDirectorsMember 2017-07-01 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:NonemployeesMember 2017-07-01 2017-09-30 0001136174 cats:EmployeesAndDirectorsMember 2017-07-01 2017-09-30 0001136174 cats:July2015ConvertibleDebentureMember cats:AcuitasMember 2015-07-31 0001136174 2015-12-31 0001136174 2016-09-30 0001136174 cats:July2015ConvertibleDebentureMember cats:AcuitasMember 2016-10-31 0001136174 2016-12-31 0001136174 cats:AcuitasWarrantsMember cats:AcuitasMember 2016-12-31 0001136174 cats:AmendedWarrantsMember 2016-12-31 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2016-12-31 0001136174 cats:ShamusWarrantsMember cats:ShamusMember 2016-12-31 0001136174 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2016-12-31 0001136174 cats:WarrantsMember 2016-12-31 0001136174 cats:EmployeesAndDirectorsMember 2016-12-31 0001136174 cats:AcuitasWarrantsMember cats:ShamusMember 2017-01-31 0001136174 cats:December2016WarrantsMember cats:AcuitasMember 2017-01-31 0001136174 cats:January2017WarrantsMember cats:AcuitasMember 2017-01-31 0001136174 cats:ShamusWarrantsMember cats:ShamusMember 2017-01-31 0001136174 cats:AcuitasMember cats:January2017ConvertibleDebentureMember 2017-01-31 0001136174 cats:AmendedWarrantsMember 2017-03-31 0001136174 cats:AmendedWarrantsMember cats:AccreditedInvestorMember 2017-03-31 0001136174 cats:AmendedWarrantsMember cats:AcuitasMember 2017-03-31 0001136174 cats:WarrantsNotSubjectToAmendmentMember 2017-03-31 0001136174 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-03-31 0001136174 cats:WarrantsMember 2017-03-31 0001136174 cats:EmployeesAndDirectorsMember 2017-03-31 0001136174 cats:JosephGunnarAndCoLLCMember us-gaap:OverAllotmentOptionMember 2017-04-28 0001136174 cats:JosephGunnarAndCoLLCMember cats:PublicOfferingMember 2017-04-28 0001136174 cats:AmendedWarrantsMember cats:AcuitasMember 2017-04-30 0001136174 cats:December2016ConvertibleDebentureMember cats:AcuitasMember 2017-04-30 0001136174 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-06-30 0001136174 cats:WarrantsMember 2017-06-30 0001136174 cats:EmployeesAndDirectorsMember 2017-06-30 0001136174 2017-09-30 0001136174 us-gaap:CertificatesOfDepositMember 2017-09-30 0001136174 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2017-09-30 0001136174 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2017-09-30 0001136174 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2017-09-30 0001136174 us-gaap:FairValueInputsLevel1Member 2017-09-30 0001136174 us-gaap:FairValueInputsLevel2Member 2017-09-30 0001136174 us-gaap:FairValueInputsLevel3Member 2017-09-30 0001136174 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2017-09-30 0001136174 cats:WarrantsMember 2017-09-30 0001136174 cats:The2010StockIncentivePlanMember 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember 2017-09-30 0001136174 cats:The2017StockIncentivePlanMember cats:EmployeesAndDirectorsMember 2017-09-30 0001136174 cats:TravelAndExpensesMember cats:ChairmanAndChiefExecutiveOfficerMember 2017-09-30 0001136174 cats:EmployeesAndDirectorsMember 2017-09-30 0001136174 2017-11-13

EX-101.SCH 7 cats-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Document - Note 1 - Basis of Consolidation and Presentation link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Short-term Debt link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Restatement of Financial Statements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 4 - Short-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 5 - Restatement of Financial Statements (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 cats-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cats-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cats-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Conversion Of December 2016 Convertible Debentures Into Common Stock [Member] Refers to the information regarding the conversion of December 2016 convertible debentures into common stock. Note To Financial Statement Details Textual statementsignificantaccountingpoliciespolicies statementnote2summaryofsignificantaccountingpoliciestables us-gaap_PaymentOfFinancingAndStockIssuanceCosts Transactions costs statementnote2summaryofsignificantaccountingpoliciesemployeeanddirectorstockoptionactivitydetails statementnote2summaryofsignificantaccountingpoliciesfairvalueassetsandliabilitiesmeasuredonarecurringbasisdetails statementnote2summaryofsignificantaccountingpoliciesfairvaluemeasurementsusingsignificantleveliiiinputsdetails statementnote2summaryofsignificantaccountingpoliciesfairvalueassumptionsdetails Operating expenses Notes To Financial Statements Notes To Financial Statements [Abstract] cats_ClassOfWarrantOrRightIssuedDuringPeriod Class of Warrant or Right, Issued During Period The number of warrants or rights issued during period. Derivatives, Policy [Policy Text Block] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] cats_WriteOffOfWarrantLiability Write-off of Warrant Liability Amount of warrant liability written off due to the elimination of the anti-dilution provision under the amendment. Fair Value Hierarchy [Domain] Common Stock Issued for Investor Relation Services [Member] Represents stock issued in lieu of cash for investor relation services. Investing activities: Fair Value, Hierarchy [Axis] Proceeds from the issuance of common stock and warrants Proceeds from Issuance of Common Stock Equity Component [Domain] us-gaap_CashUninsuredAmount Cash, Uninsured Amount Equity Components [Axis] Deferred revenue us-gaap_IncreaseDecreaseInDeferredRevenue cats_WarrantTerm Warrant Term Period of time between issuance and maturity of warrants. Accounts payable and other accrued liabilities us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Travel and Expenses [Member] Represents travel and expenses. Short term debt, related party, discount Preferred stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) New Accounting Pronouncements, Policy [Policy Text Block] Derivative Financial Instruments, Liabilities [Member] Asset Class [Axis] Related Party Transaction [Domain] Related Party Transaction [Axis] Asset Class [Domain] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount us-gaap_DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net Basic and diluted net loss from operations per share: (in dollars per share) cats_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWriteOff Write off of warrants Amount of write-off of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. cats_DeferredSalarySettledByShares Deferred Salary Settled by Shares The amount deferred salary balance that was settled by shares. Related Party [Axis] Related Party [Domain] us-gaap_RepaymentsOfLongTermCapitalLeaseObligations Capital lease obligations Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_RepaymentsOfConvertibleDebt Repayments of Convertible Debt Payments on convertible debenture Basic weighted number of shares outstanding (in shares) us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued Common stock issued for conversion of debt and accrued interest Scenario, Unspecified [Domain] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Scenario [Axis] Debt Conversion, Name [Domain] Debt Conversion Description [Axis] Nonmonetary Transaction Type [Domain] Deferred rent Nonmonetary Transaction Type [Axis] Debt Disclosure [Text Block] Expected volatility Domestic Tax Authority [Member] Healthcare services revenues Proceeds from issuance of senior promissory note, related party Income Tax Authority [Domain] Warrants [Member] Represents warrants. Income Tax Authority [Axis] us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Cash and Cash Equivalents, Policy [Policy Text Block] Customer Concentration Risk [Member] Maximum [Member] Range [Domain] Minimum [Member] Customer [Axis] Reverse stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Concentration Risk Type [Domain] Significant Accounting Policies [Text Block] Range [Axis] Customer [Domain] Accounting Policies [Abstract] Statement of Financial Position [Abstract] Concentration Risk Type [Axis] Relationship to Entity [Domain] Furniture and Equipment [Member] Represents furniture and equipment. Title of Individual [Axis] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaids and other current assets us-gaap_LiabilitiesFairValueDisclosure Total liabilities us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share cats_RepaymentOfAdvanceFromRelatedParty Payment on advance from related party The cash outflow for the payment of advance from related party. Sales Revenue, Net [Member] Statement of Cash Flows [Abstract] Proceeds from advance from related party The cash inflow associated with advance from related party. Accounts Receivable [Member] Fair Value by Liability Class [Domain] Liability Class [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Axis] Proceeds from issuance of bridge loan Property and equipment acquired through capital leases and other financing Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Supplemental disclosure of non-cash activity Change in fair value us-gaap_IncreaseDecreaseInAccountsReceivable Receivables Cancelled (in shares) Cancelled (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross cats_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Additional Securities Called by Each Warrant or Right Number of additional securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. Amended Warrants [Member] Represents the amended warrants. us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services us-gaap_ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Warrants Not Subject to Amendment [Member] Information regarding the warrants not subject to certain amendments. cats_SharesIssuedPricePerShareNet Shares Issued, Price Per Share, Net The per share value of shares issued, net of underwriter costs, discounts, and commissions. Convertible Debentures [Member] Represents the convertible debentures. us-gaap_StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues Joseph Gunnar & Co., LLC [Member] Represents the underwriter Joseph Gunnar & Co., LLC. cats_AdditionalSharesAvailableForPurchase Additional Shares Available for Purchase The maximum number of additional shares available for purchase under certain underwriting agreements. Public Offering [Member] Related to the public offering. us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Stockholders' Equity/(Deficit) Provision for income taxes Income Tax Expense (Benefit) Accumulated deficit us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Deferred rent and other long-term liabilities Statement [Table] Issuance (exercise) of warrants, net Income Statement [Abstract] Financing activities: The 2010 Stock Incentive Plan [Member] Information related to the 2010 stock incentive plan. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Five Customers [Member] Concentration risk information related to five customers. Capital leases Class of Stock [Axis] Award Type [Axis] Equity Award [Domain] Change in fair value of derivative liability Fair value adjustment on derivative liability Acuitas Warrants [Member] Information pertaining to the Acuitas Warrants. Fair Value of Financial Instruments, Policy [Policy Text Block] Prepaids and other current assets Expected dividend us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Risk-free interest rate Long-term liabilities Weighted average expected lives in years (Year) us-gaap_LiabilitiesCurrent Total current liabilities Common stock issued for exercise of warrants cats_CommonStockIssuedForExerciseOfWarrants The fair value of stock issued in noncash financing activities related to the exercise of warrants. Changes in current assets and liabilities: Revenues: Short term debt, related party, net of discount $0 and $216, respectively Due to Related Parties, Current Earnings Per Share, Policy [Policy Text Block] December 2016 Convertible Debenture [Member] Information pertaining to the 8% Series B Convertible Debenture due March 31, 2017 (the December 2016 Convertible Debenture). Shamus Warrants [Member] Information pertaining to the Shamus Warrants. Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] us-gaap_OperatingExpenses Total operating expenses Other income Income Tax, Policy [Policy Text Block] December 2016 Warrants [Member] Information pertaining to the December 2016 warrants. cats_ClassOfWarrantOrRightPercentOfSecuritiesCalledByWarrantsOrRightsUponConversion Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion Represents the percentage of securities in which the class of warrant or right me be converted upon conversion, including, but not limited to a debt instrument. Share-based Compensation, Stock Options, Activity [Table Text Block] General and administrative Accounting Changes and Error Corrections [Text Block] Derivative liability us-gaap_OperatingIncomeLoss Loss from operations Deferred revenue Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Amendment Flag Common stock, $0.0001 par value; 500,000,000 shares authorized; 15,889,171 and 9,214,743 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively Fair value adjustment on warrant liability Fair Value Adjustment of Warrants Change in fair value of warrant liability Common stock, shares authorized (in shares) Loss on conversion of note Gain (Loss) on Conversion of Debt Loss on conversion of convertible debenture The amount of gain (loss) recognized on the conversion of debt instruments. Common stock, shares issued (in shares) Common stock issued for services Deposits and other assets Common stock, par value (in dollars per share) Share-based compensation expense Share-based Compensation Short-term Debt, Type [Domain] Current Fiscal Year End Date Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding Amortization of debt discount and issuance costs included in interest expense Accredited Investor [Member] Represents an accredited investor. Short-term Debt, Type [Axis] Cost of Sales, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Cost of healthcare services Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding Preferred stock, shares issued (in shares) Document Type EX-101.PRE 11 cats-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 13, 2017
Document Information [Line Items]
Entity Registrant Name	CATASYS, INC.
Entity Central Index Key	0001136174
Trading Symbol	cats
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		15,889,171
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands

Sep. 30, 2017

Dec. 31, 2016

Current assets

Cash and cash equivalents

$ 6,926

$ 851

Receivables, net of allowance for doubtful accounts of $277 and $0, respectively

709

1,052

Prepaids and other current assets

307

420

Total current assets

7,942

2,323

Long-term assets

Property and equipment, net of accumulated depreciation of $1,751 and $1,620, respectively

553

410

Deposits and other assets

371

Total Assets

8,866

3,104

Current liabilities

Accounts payable

806

870

Accrued compensation and benefits

901

2,089

Deferred revenue

3,180

1,525

Other accrued liabilities

579

575

Short term debt, related party, net of discount $0 and $216, respectively

9,796

Derivative liability

8,122

Total current liabilities

5,466

22,977

Long-term liabilities

Deferred rent and other long-term liabilities

117

Capital leases

Warrant liabilities

5,307

Total Liabilities

5,562

28,432

Stockholders' equity/(deficit)

Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding

Common stock, $0.0001 par value; 500,000,000 shares authorized; 15,889,171 and 9,214,743 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively

^[1]

Additional paid-in-capital

293,945

254,390

Accumulated deficit

(290,643)

(279,719)

Total Stockholders' Equity/(Deficit)

3,304

(25,328)

Total Liabilities and Stockholders' Equity/(Deficit)

$ 8,866

$ 3,104

[1]	The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017.

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares
Receivables, allowance for doubtful accounts \| $	$ 277	$ 277	$ 0
Property and equipment, accumulated dereciation \| $	1,751	1,751	1,620
Short term debt, related party, discount \| $	$ 0	$ 0	$ 216
Preferred stock, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0	0
Preferred stock, shares outstanding (in shares)	0	0	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000	500,000,000
Common stock, shares issued (in shares)	15,889,171	15,889,171	9,214,743
Common stock, shares outstanding (in shares)	15,889,171	15,889,171	9,214,743
Reverse Stock Split [Member]
Reverse stock split	6	6

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2017

Sep. 30, 2016

Sep. 30, 2017

Sep. 30, 2016

Revenues:

Healthcare services revenues

$ 1,195,000

$ 1,336,000

$ 4,682,000

$ 3,287,000

Operating expenses

Cost of healthcare services

1,664,000

1,253,000

4,361,000

3,381,000

General and administrative

2,575,000

2,195,000

8,144,000

6,518,000

Depreciation and amortization

47,000

38,000

131,000

102,000

Total operating expenses

4,286,000

3,486,000

12,636,000

10,001,000

Loss from operations

(3,091,000)

(2,150,000)

(7,954,000)

(6,714,000)

Other income

16,000

15,000

44,000

90,000

Interest expense

(1,000)

(3,215,000)

(3,408,000)

(4,139,000)

Loss on conversion of note

(1,356,000)

Loss on issuance of common stock

(145,000)

Change in fair value of derivative liability

(3,484,000)

132,000

(6,328,000)

Change in fair value of warrant liability

(2,000)

1,423,000

1,767,000

673,000

Loss from operations before provision for income taxes

(3,078,000)

(7,411,000)

(10,920,000)

(16,418,000)

Provision for income taxes

2,000

4,000

7,000

Net Loss

$ (3,080,000)

$ (7,413,000)

$ (10,924,000)

$ (16,425,000)

Basic and diluted net loss from operations per share: (in dollars per share)

$ (0.19)

$ (0.81)

$ (0.84)

$ (1.79)

Basic weighted number of shares outstanding (in shares)

^[1]

15,889

9,174

13,031

9,170

[1]	The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017.

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)		3 Months Ended	9 Months Ended
	Apr. 25, 2017	Sep. 30, 2017	Sep. 30, 2017
Reverse Stock Split [Member]
Reverse stock split	6	6	6

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net loss	$ (10,924,000)	$ (16,425,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	131,000	102,000
Amortization of debt discount and issuance costs included in interest expense	3,335,000	3,673,000
Provision for doubtful accounts	307,000	46,000
Deferred rent	(60,000)	(52,000)
Share-based compensation expense	191,000	523,000
Common stock issued for services	181,000
Loss on conversion of convertible debenture	1,356,000
Loss on issuance of common stock	145,000
Fair value adjustment on warrant liability	(1,767,000)	(673,000)
Fair value adjustment on derivative liability	(132,000)	6,328,000
Changes in current assets and liabilities:
Receivables	36,000	(345,000)
Prepaids and other current assets	113,000	270,000
Deferred revenue	1,655,000	1,548,000
Accounts payable and other accrued liabilities	85,000	554,000
Net cash used by operating activities	(5,348,000)	(4,451,000)
Investing activities:
Purchases of property and equipment	(274,000)	(102,000)
Deposits and other assets		16,000
Net cash used by investing activities	(274,000)	(86,000)
Financing activities:
Proceeds from the issuance of common stock and warrants	16,458,000
Proceeds from issuance of bridge loan	1,300,000
Payments on convertible debenture	(4,363,000)
Proceeds from issuance of senior promissory note, related party		5,505,000
Proceeds from advance from related party		225,000
Payment on advance from related party		(225,000)
Transactions costs	(1,667,000)
Capital lease obligations	(31,000)	(41,000)
Net cash provided by financing activities	11,697,000	5,464,000
Net increase in cash and cash equivalents	6,075,000	927,000
Cash and cash equivalents at beginning of period	851,000	916,000
Cash and cash equivalents at end of period	6,926,000	1,843,000
Supplemental disclosure of cash paid
Interest
Income taxes	40,000	46,000
Supplemental disclosure of non-cash activity
Common stock issued for exercise of warrants		45,000
Property and equipment acquired through capital leases and other financing		34,000
Common Stock Issued Upon Settlement of Deferred Compensation to Officer [Member]
Supplemental disclosure of non-cash activity
Common stock issued upon settlement of deferred compensation to officer	1,122,000
Common Stock Issued for Conversion of Debt and Accrued Interest [Member]
Supplemental disclosure of non-cash activity
Common stock issued for conversion of debt and accrued interest	$ 7,163,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Consolidation and Presentation	9 Months Ended
Note 1 - Basis of Consolidation and Presentation	Sep. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Consolidation and Presentation The accompanying unaudited condensed consolidated financial statements for Catasys, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and instructions to Form 10 -Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto included in our most recent Annual Report on Form 10 -K for the year-ended December 31, 2016, from which the balance sheet, as of December 31, 2016, have been derived.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note

Summary of Significant Accounting Policies

Revenue Recognition

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts

may

include a minimum performance guarantee; we reserve a portion of the fees that

may

be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are

not

subject to the performance guarantees, we recognize the case rate ratably over the

twelve

months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.

Cost of Services

third

party administrators for processing these claims. Salaries and fees charged by our

third

party administrators for processing claims are expensed when incurred and healthcare provider claims payments are recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-service basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the eOn

Trak

database within the contracted timeframe, with all required billing elements correctly completed by the service provider.

Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid investments with an original maturity of

three

months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality financial institutions

. The deposited cash

may

exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of

September 30, 2017,

we had

$6.8

million in cash and cash equivalents exceeding federally insured limits.

For the

nine

months ended

September 30, 2017,

three

customers accounted for approximately

90%

of the Company’s revenues and

five

customers accounted for approximately

96%

of accounts receivable.

Basic and Diluted

Income (

Loss

)

per Share

Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the

weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock and dilutive common equivalent shares outstanding during the period.

Common equivalent shares, consisting of

2,255,381

and

1,178,821

shares for the

nine

months ended

September 30, 2017

and

2016,

respectively, issuable upon the exercise of

stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

Share-Based Compensation

Our

2017

Stock Incentive Plan (the

“2017

Plan”), provides for the issuance of up to

2,333,334

shares of our common stock

and an additional

243,853

shares of our common stock that are represented by awards granted under our

2010

Stock Incentive Plan (the

“2010

Plan”). Incentive stock options (ISOs) under Section

422A

of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire

later than

ten

years from the date of grant and employee and board of director awards generally vest over

three

five

years. At

September 30, 2017,

we had

243,853

vested and unvested shares outstanding and

2,333,334

shares available for future awards under the

2017

Plan.

hare-based compensation expense attributable to continuing operations were

$32,000

and

$191,000

for the

three

and

nine

months ended

September 30, 2017,

compared with

$174,000

and

$523,000

for the same periods in

2016,

respectively.

Stock Options

– Employees and Directors

measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations.

Share-based compensation expense recognized

for employees and directors for the

three

and

nine

months ended

September 30, 2017

was

$32,000

and

$191,000,

compared with

$174,000

and

$523,000,

for the same periods in

2016,

respectively.

consolidated statements of operations for the

three

and

nine

months ended

September 30, 2017

and

2016

is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

There were

options granted to employees and directors during the

three

and

nine

months ended

September 30, 2017

and

2016,

respectively, under the

2017

Plan. Employee and director stock option activity for the

three

and

nine

months ended

September 30, 2017

are as follows:

				Weighted Avg.
	Shares			Exercise Price
Balance December 31, 2016		244,046		$	39.06

Granted		-		$	-
Cancelled		(193	)	$	(245.47	)

Balance March 31, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance June 30, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance September 30, 2017		243,853		$	38.90

three

and

nine

months ended

September 30, 2017

and

2016,

reflects the application of the simplified method prescribed in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”)

No.

107

(as amended by SAB

110

), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of

September 30, 2017,

there was

$127,500

of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the

2017

Plan. That cost is expected to be recognized over a weighted-average period of approximately

1.02

years.

Stock Options and Warrants

– Non-employees

We account for the issuance of options and warrants

for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.

. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.

There were

options issued to non-employees for the

three

and

nine

months ended

September 30, 2017

or during the same periods in

2016.

There was

share based compensation expense relating to stock options and warrants recognized for the non-employees for the

three

and

nine

months ended

September 30, 2017

or during the same periods in

2016.

Common Stock

April 2017,

we entered into an underwriting agreement with Joseph Gunnar & Co., LLC (“Joseph Gunnar”), as underwriter in connection with a public offering of the Company’s securities. Pursuant to the underwriting agreement, we agreed to issue and sell an aggregate

3,125,000

shares of common stock at a public offering price of

$4.80

per share, and the purchase price to the underwriter after discounts and commission was

$4.464

per share. The closing of the offering occurred on

April 28, 2017.

We received

$15.0

million in gross proceeds in connection with the offering.

Pursuant to the underwriting agreement with Joseph Gunnar, we

granted the underwriters a

day over-allotment option to purchase up to

468,750

additional shares of common stock at the public offering price less the applicable underwriter discount. In

May,

the underwriter acquired an additional

303,750

shares pursuant to such over-allotment option. We received

$1.5

million in gross proceeds in connection with the over-allotment option.

In connection with the public offering, our common stock began trading on the NASDAQ Capital Market

(“NASDAQ”) under the symbol “CATS” beginning on

April 26, 2017.

April 2017,

several investors, including Acuitas Group Holdings, LLC (“Acuitas”),

one hundred

percent (

100%

) of which is owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and Shamus, LLC (“Shamus”), a Company owned by David E. Smith, a member of our board of directors, exercised their option to convert their

convertible debentures and received

2,982,994

shares of common stock. There was a loss on the conversion of the convertible debentures of

$1.4

million for the

nine

months ended

September 30, 2017.

April 2017,

Terren S. Peizer agreed to settle his deferred salary balance of

$1.1

million for

233,734

shares of common stock.

As a result, we recognized a loss on settlement of liability totaling

$83,807

which is recorded to loss on issuance of common stock.

April 2017,

we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a

-for-

reverse stock split

of our common stock, pursuant to which each

six

shares of issued and outstanding common stock converted into

one

share of common stock. Proportionate voting rights and other rights of common stock holders were

not

affected by the reverse stock split.

fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares.

six

and, as applicable, multiplying the exercise price by

six

as a result of the reverse stock split.

There were

and

28,985

shares of common stock issued in exchange for investor relations services during the

three

and

nine

months ended

September 30, 2017

and

common stock issued in exchange for investor relations services during the same period in

2016.

Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods.

Income Taxes

We have

recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of

September 30, 2017.

As such, we have

not

recorded a provision for income tax for the period ended

September 30, 2017.

We utilize the liability method of accounting for income taxes as set forth in ASC

740,

Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than

not

that some of the deferred tax assets will

not

be realized.

assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than

50%

likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that

may

potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than

50%

likelihood that a tax benefit will be sustained,

tax benefit has been recognized in the financial statements. Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended

September 30, 2017

should be realized.

Fair Value Measurements

) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (

) an entity

’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of

three

broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The

three

levels of the fair value hierarchy are described below:

Level Input:		Input Definition:
Level I		Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II		Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III		Unobservable inputs that reflect management ’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at

September 30, 2017

for assets and liabilities measured at fair value:

	Balance at September 30, 2017


(Amounts in thousands)	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		41		41
Total liabilities		-		-		41		41

Financial instruments classified as Level

III in the fair value hierarchy as of

September 30, 2017,

represent our liabilities measured at market value on a recurring basis which include warrant liabilities resulting from recent debt financing. In accordance with current accounting rules, the warrant liabilities with anti-dilution protection are being marked-to-market each quarter-end until they are completely settled or expire. The warrants are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See

Warrant Liabilities

below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the

three

and

nine

months ended

September 30, 2017:

	Level III				Level III
	Warrant				Derivative
(Dollars in thousands)	Liabilities			(Dollars in thousands)	Liabilities
Balance as of December 31, 2016	$	5,307		Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405		Issuance of convertible debentures		-
Change in fair value		5,181		Change in fair value		10,596
Balance as of March 31, 2017	$	12,893		Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		269		Issuance of convertible debentures		-
Change in fair value		(6,950	)	Change in fair value		(10,728	)
Write off of warrants		(6,174	)	Write off of derivative liability		(7,990	)
Balance as of June 30, 2017	$	38		Balance as of June 30, 2017	$	-

Issuance (exercise) of warrants, net		-		Issuance of convertible debentures		-
Expiration of warrants		-		Expiration of warrants		-
Change in fair value		2		Change in fair value		-
Balance as of September 30, 2017	$	40		Balance as of September 30, 2017	$	-

Property and Equipment

two

seven

years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically

five

seven

years.

Warrant Liabilities

March 2017,

we entered into amendments with the holders of certain outstanding warrants issued on

April 17, 2015

and

July 30, 2015

to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of

$5.3

million on our balance sheet as of

December 31, 2016.

Such amendments were contingent upon and did

not

take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional

shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of

11,049

shares of common stock, did

not

agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor, who received additional

warrants to purchase

31,167

and

13,258

shares of our common stock. In addition, several warrant agreements that had anti-dilution protection had a provision in the agreement that upon an up-listing to NASDAQ, the anti-dilution protection would be removed. The up-listing to NASDAQ occurred on

April 26, 2017.

The elimination of the anti-dilution provision resulted in the write-off of

$6.2

million of the warrant liability as of

September 30, 2017.

January 2017,

we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which we receive

d aggregate gross proceeds of

$1,300,000

(the “Loan Amount”) in consideration of the issuance of (i) an

Series B Convertible Debenture due

March 31, 2017 (

the

“January 2017

Convertible Debenture”) and (ii)

five

-year warrants to purchase shares of our common stock in an amount equal to

one hundred

percent (

100%

) of the initial number of shares of common stock issuable upon the conversion of the

January 2017

Convertible Debenture, at an exercise price of

$5.10

per share (the

“January 2017

Warrants”). In addition, any warrants issued in conjunction with the

December 2016

Convertible Debenture currently outstanding with Acuitas have been increased by an additional

25%

warrant coverage, exercisable for an aggregate of

137,883

shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the

January 2017

Convertible Debenture to

April 30, 2017

or until we completes a public offering, whichever came first. In

April 2017,

we used the net proceeds from the public offering to repay the Loan Amount including interest of

$1.3

million.

The

January 2017

Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the

January 2017

Warrants will be adjusted if we issue shares of our common stock at a price that is less than the then exercise price of the

January 2017

Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the

January 2017

Warrants, (ii) such time as the

January 2017

Warrants are exercised or (iii) contemporaneously with the listing of our shares of common stock on a registered national securities exchange.

In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the

December 2016

Convertible Debenture were increased from

75%

100%

warrant coverage, exercisable for an aggregate of

14,706

shares of the Company’s common stock.

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions

	September 30 , 201 7
Expected volatility		93.56	%
Risk-free interest rate		1.62	%
Weighted average expected lives in years		2.54
Expected dividend		0	%

We have issued warrants

to purchase common stock in

February 2012,

April 2015,

July 2015,

August 2016,

December 2016,

January 2017,

February 2017,

March 2017,

April 2017,

and

June 2017.

Some of the warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

r the

three

and

nine

months ended

September 30, 2017,

we recognized a loss of

$2,000

and a gain of

$1.8

million, respectively, compared with a gain of

$1.4

million and

$673,000

for the same periods in

2016,

respectively, related to the revaluation of our warrant liabilities.

Derivative Liability

July 2015,

we entered into

$3.55

million

12%

Original Issue Discount Convertible Debenture due

January 18, 2016

with Acuitas (the

“July 2015

Convertible Debenture”). The conversion price of the

July 2015

Convertible Debenture is

$11.40

per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case

may

be. In

October 2016,

we entered into an amendment of the

July 2015

Convertible Debenture which extended the maturity date of the Convertible Debenture from

January 18, 2016

January 18, 2017.

In addition, the conversion price of the

July 2015

Convertible Debenture was subsequently adjusted to

$1.80

per share. The

July 2015

Convertible Debentures are unsecured, bear interest at a rate of

12%

per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and are subject to mandatory prepayment upon the consummation of certain future financings. Acuitas agreed to extend the maturity date of the

July 2015

Convertible Debenture to

April 30, 2017

or until we completed a public offering, whichever came first. In

April 2017,

the

July 2015

Convertible Debenture was converted into

2,385,111

shares of common stock and the derivative liability was written off.

r the

three

and

nine

months ended

September 30, 2017,

we recognized a gain of

and

$132,000,

respectively, compared with a loss of

$3.5

million and

$6.3

million for the same periods in

2016,

related to the revaluation of our derivative liability.

Recently Issued or Newly Adopted Accounting Standards

April 2016,

the FASB issued Accounting Standards Update (“ASU”)

2016

10,

Revenue from Contracts with Customers (Topic

606

)

(“ASU

2016

10”

), which amends certain aspects of the Board’s new revenue standard, ASU

2014

09,

Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU

2014

which is effective for annual and interim periods beginning after

December 15, 2017.

We are currently evaluating the potential impact of this standard on our consolidated financial statements, as well as the available transition methods. We are currently assessing whether the adoption of ASU

2016

will have a material effect on our consolidated financial position or results of operations.

March 2016,

the FASB issued ASU

2016

09,

Compensation — Stock Compensation (Topic

718

): Improvements to Employee Share-Based Payment Accounting

(“ASU

2016

09”

), which outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The standard is effective beginning

December 15, 2016,

and interim periods within those annual periods. Early adoption is permitted.

The adoption of ASU

2016

did

not

have a material effect on our consolidated financial position or results of operations.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Related Party Disclosure	9 Months Ended
Note 3 - Related Party Disclosure	Sep. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 3 . Related Party Disclosure In January 2017, we entered into the Subscription Agreement with Acuitas pursuant to which we receive d aggregate gross proceeds of $1.3 million and warrants to purchase 254,904 shares of common stock. In April 2017, we used the net proceeds from the public offering to repay the Loan Amount including interest of $1.3 million. In January 2017, in connection with the Subscription Agreement described above, the number of Acuitas warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 137,883 shares of our common stock. In March 2017, we entered into an amendment with Acuitas of certain outstanding warrants issued in July 2015 to eliminate certain anti-dilution provisions in such warrants. Such amendment was contingent upon and did not take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional .2 shares of common stock. Acuitas received additional warrants to purchase 31,167 shares of our common stock in April 2017. In April 2017, Acuitas purchased 181,154 shares of common stock for $869,539 in proceeds in connection with the public offering. In April 2017, Acuitas converted its July 2015 convertible debenture totaling $4.3 million of principal and interest into 2,385,111 shares of common stock. In April 2017, we used net proceeds from the public offering to repay Acuitas the December 2016 8% convertible debenture with accrued interest of $2.9 million. In April 2017, Terren S. Peizer agreed to settle his deferred salary balance of $1.1 million for 233,734 shares of common stock , resulting in a loss on settlement of liability totaling $83,807 recorded to loss on issuance of common stock. In addition, we have accounts payable outstanding with Mr. Peizer for travel and expenses of approximately $223,000 as of September 30, 2017. In January 2017, in connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the December 2016 Convertible Debenture were increased from 75% to 100% warrant coverage, exercisable for an aggregate of 14,706 shares of our common stock. In March 2017, Shamus converted $1.3 million of their December 2016 Convertible Debentures and accrued interest for 2 76,204 shares of our common stock.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Short-term Debt	9 Months Ended
Note 4 - Short-term Debt	Sep. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 . Short-term Debt In January 2017, we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which we received aggregate gross proceeds of $1,300,000 (the “Loan Amount”) in consideration of the issuance of (i) an 8% Series B Convertible Debenture due March 31, 2017 ( the “January 2017 Convertible Debenture”) and (ii) 254,904 five -year warrants to purchase shares of the Company’s common stock which is equal to one hundred percent ( 100% ) of the initial number of shares of common stock issuable upon the conversion of the January 2017 Convertible Debenture, at an exercise price of $5.10 per share (the “January 2017 Warrants”). In addition, any warrants issued in conjunction with the December 2016 Convertible Debenture currently outstanding with Acuitas have been increased by an additional 25% warrant coverage, exercisable for an aggregate of 137,883 shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the January 2017 Convertible Debenture to April 30, 2017 or until we completed a public offering, whichever came first. In April 2017, we used the net proceeds from the public offering to repay the Loan Amount including interest of $1.3 million.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Restatement of Financial Statements	9 Months Ended
Note 5 - Restatement of Financial Statements	Sep. 30, 2017
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	N ote 5 . Restatement of Financial Statements The prior year financial statements have been retroactively restated to reflect the 1 -for- 6 reverse-stock split that occurred on April 25, 2017.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis or an upfront case rate based on enrolled members. To the extent our contracts

may

include a minimum performance guarantee; we reserve a portion of the fees that

may

be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are

not

subject to the performance guarantees, we recognize the case rate ratably over the

twelve

months of our program. We recognize any fees from sharing in the savings generated from enrolled members when we receive payment.

Cost of Sales, Policy [Policy Text Block]

Cost of Services

third

party administrators for processing these claims. Salaries and fees charged by our

third

Trak

database within the contracted timeframe, with all required billing elements correctly completed by the service provider.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid investments with an original maturity of

three

. The deposited cash

may

exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of

September 30, 2017,

we had

$6.8

million in cash and cash equivalents exceeding federally insured limits.

For the

nine

months ended

September 30, 2017,

three

customers accounted for approximately

90%

of the Company’s revenues and

five

customers accounted for approximately

96%

of accounts receivable.

Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted

Income (

Loss

)

per Share

Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the

Common equivalent shares, consisting of

2,255,381

and

1,178,821

shares for the

nine

months ended

September 30, 2017

and

2016,

respectively, issuable upon the exercise of

stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-Based Compensation

Our

2017

Stock Incentive Plan (the

“2017

Plan”), provides for the issuance of up to

2,333,334

shares of our common stock

and an additional

243,853

shares of our common stock that are represented by awards granted under our

2010

Stock Incentive Plan (the

“2010

Plan”). Incentive stock options (ISOs) under Section

422A

later than

ten

years from the date of grant and employee and board of director awards generally vest over

three

five

years. At

September 30, 2017,

we had

243,853

vested and unvested shares outstanding and

2,333,334

shares available for future awards under the

2017

Plan.

hare-based compensation expense attributable to continuing operations were

$32,000

and

$191,000

for the

three

and

nine

months ended

September 30, 2017,

compared with

$174,000

and

$523,000

for the same periods in

2016,

respectively.

Stock Options

– Employees and Directors

Share-based compensation expense recognized

for employees and directors for the

three

and

nine

months ended

September 30, 2017

was

$32,000

and

$191,000,

compared with

$174,000

and

$523,000,

for the same periods in

2016,

respectively.

consolidated statements of operations for the

three

and

nine

months ended

September 30, 2017

and

2016

There were

options granted to employees and directors during the

three

and

nine

months ended

September 30, 2017

and

2016,

respectively, under the

2017

Plan. Employee and director stock option activity for the

three

and

nine

months ended

September 30, 2017

are as follows:

				Weighted Avg.
	Shares			Exercise Price
Balance December 31, 2016		244,046		$	39.06

Granted		-		$	-
Cancelled		(193	)	$	(245.47	)

Balance March 31, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance June 30, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance September 30, 2017		243,853		$	38.90

three

and

nine

months ended

September 30, 2017

and

2016,

reflects the application of the simplified method prescribed in Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”)

No.

107

(as amended by SAB

110

), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of

September 30, 2017,

there was

$127,500

of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the

2017

Plan. That cost is expected to be recognized over a weighted-average period of approximately

1.02

years.

Stock Options and Warrants

– Non-employees

We account for the issuance of options and warrants

. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.

There were

options issued to non-employees for the

three

and

nine

months ended

September 30, 2017

or during the same periods in

2016.

There was

share based compensation expense relating to stock options and warrants recognized for the non-employees for the

three

and

nine

months ended

September 30, 2017

or during the same periods in

2016.

Stockholders' Equity, Policy [Policy Text Block]

Common Stock

April 2017,

3,125,000

shares of common stock at a public offering price of

$4.80

per share, and the purchase price to the underwriter after discounts and commission was

$4.464

per share. The closing of the offering occurred on

April 28, 2017.

We received

$15.0

million in gross proceeds in connection with the offering.

Pursuant to the underwriting agreement with Joseph Gunnar, we

granted the underwriters a

day over-allotment option to purchase up to

468,750

additional shares of common stock at the public offering price less the applicable underwriter discount. In

May,

the underwriter acquired an additional

303,750

shares pursuant to such over-allotment option. We received

$1.5

million in gross proceeds in connection with the over-allotment option.

In connection with the public offering, our common stock began trading on the NASDAQ Capital Market

(“NASDAQ”) under the symbol “CATS” beginning on

April 26, 2017.

April 2017,

several investors, including Acuitas Group Holdings, LLC (“Acuitas”),

one hundred

percent (

100%

convertible debentures and received

2,982,994

shares of common stock. There was a loss on the conversion of the convertible debentures of

$1.4

million for the

nine

months ended

September 30, 2017.

April 2017,

Terren S. Peizer agreed to settle his deferred salary balance of

$1.1

million for

233,734

shares of common stock.

As a result, we recognized a loss on settlement of liability totaling

$83,807

which is recorded to loss on issuance of common stock.

April 2017,

we filed a certificate of amendment to our Certificate of Incorporation, as amended and in effect, with the Secretary of State of the State of Delaware, implementing a

-for-

reverse stock split

of our common stock, pursuant to which each

six

shares of issued and outstanding common stock converted into

one

share of common stock. Proportionate voting rights and other rights of common stock holders were

not

affected by the reverse stock split.

fractional shares of common stock were issued as a result of the reverse stock split; stockholders were paid cash in lieu of any such fractional shares.

six

and, as applicable, multiplying the exercise price by

six

as a result of the reverse stock split.

There were

and

28,985

shares of common stock issued in exchange for investor relations services during the

three

and

nine

months ended

September 30, 2017

and

common stock issued in exchange for investor relations services during the same period in

2016.

Generally, the costs associated with shares issued for services are amortized to the related expense on a straight-line basis over the related service periods.

Income Tax, Policy [Policy Text Block]

Income Taxes

We have

recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of

September 30, 2017.

As such, we have

not

recorded a provision for income tax for the period ended

September 30, 2017.

We utilize the liability method of accounting for income taxes as set forth in ASC

740,

not

that some of the deferred tax assets will

not

be realized.

50%

likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that

may

potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than

50%

likelihood that a tax benefit will be sustained,

September 30, 2017

should be realized.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value Measurements

) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (

) an entity

’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of

three

levels of the fair value hierarchy are described below:

Level Input:		Input Definition:
Level I		Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II		Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III		Unobservable inputs that reflect management ’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at

September 30, 2017

for assets and liabilities measured at fair value:

	Balance at September 30, 2017


(Amounts in thousands)	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		41		41
Total liabilities		-		-		41		41

Financial instruments classified as Level

III in the fair value hierarchy as of

September 30, 2017,

Warrant Liabilities

below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the

three

and

nine

months ended

September 30, 2017:

	Level III				Level III
	Warrant				Derivative
(Dollars in thousands)	Liabilities			(Dollars in thousands)	Liabilities
Balance as of December 31, 2016	$	5,307		Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405		Issuance of convertible debentures		-
Change in fair value		5,181		Change in fair value		10,596
Balance as of March 31, 2017	$	12,893		Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		269		Issuance of convertible debentures		-
Change in fair value		(6,950	)	Change in fair value		(10,728	)
Write off of warrants		(6,174	)	Write off of derivative liability		(7,990	)
Balance as of June 30, 2017	$	38		Balance as of June 30, 2017	$	-

Issuance (exercise) of warrants, net		-		Issuance of convertible debentures		-
Expiration of warrants		-		Expiration of warrants		-
Change in fair value		2		Change in fair value		-
Balance as of September 30, 2017	$	40		Balance as of September 30, 2017	$	-

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

two

seven

years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically

five

seven

years.

Warrant Liabilities, Policy [Policy Text Block]

Warrant Liabilities

March 2017,

we entered into amendments with the holders of certain outstanding warrants issued on

April 17, 2015

and

July 30, 2015

to eliminate certain anti-dilution provisions in such warrants, which caused us to reflect an associated liability of

$5.3

million on our balance sheet as of

December 31, 2016.

Such amendments were contingent upon and did

not

take effect until the closing of the public offering. For each warrant share underlying the warrants so amended, the holder received the right to purchase an additional

shares of common stock. Two of the holders of such warrants, which owners hold warrants to purchase an aggregate of

11,049

shares of common stock, did

not

agree to the amendment. The warrant holders agreeing to the amendment include Acuitas and another accredited investor, who received additional

warrants to purchase

31,167

and

13,258

April 26, 2017.

The elimination of the anti-dilution provision resulted in the write-off of

$6.2

million of the warrant liability as of

September 30, 2017.

January 2017,

we entered into a Subscription Agreement (the “Subscription Agreement”) with Acuitas, pursuant to which we receive

d aggregate gross proceeds of

$1,300,000

(the “Loan Amount”) in consideration of the issuance of (i) an

Series B Convertible Debenture due

March 31, 2017 (

the

“January 2017

Convertible Debenture”) and (ii)

five

-year warrants to purchase shares of our common stock in an amount equal to

one hundred

percent (

100%

) of the initial number of shares of common stock issuable upon the conversion of the

January 2017

Convertible Debenture, at an exercise price of

$5.10

per share (the

“January 2017

Warrants”). In addition, any warrants issued in conjunction with the

December 2016

Convertible Debenture currently outstanding with Acuitas have been increased by an additional

25%

warrant coverage, exercisable for an aggregate of

137,883

shares of the Company’s common stock. Acuitas agreed to extend the maturity date of the

January 2017

Convertible Debenture to

April 30, 2017

or until we completes a public offering, whichever came first. In

April 2017,

we used the net proceeds from the public offering to repay the Loan Amount including interest of

$1.3

million.

The

January 2017

Warrants include, among other things, price protection provisions pursuant to which, subject to certain exempt issuances, the then exercise price of the

January 2017

Warrants will be adjusted if we issue shares of our common stock at a price that is less than the then exercise price of the

January 2017

Warrants. Such price protection provisions will remain in effect until the earliest of (i) the termination date of the

January 2017

Warrants, (ii) such time as the

January 2017

Warrants are exercised or (iii) contemporaneously with the listing of our shares of common stock on a registered national securities exchange.

In connection with the Subscription Agreement described above, the number of Shamus warrants issued as part of the

December 2016

Convertible Debenture were increased from

75%

100%

warrant coverage, exercisable for an aggregate of

14,706

shares of the Company’s common stock.

The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions

	September 30 , 201 7
Expected volatility		93.56	%
Risk-free interest rate		1.62	%
Weighted average expected lives in years		2.54
Expected dividend		0	%

We have issued warrants

to purchase common stock in

February 2012,

April 2015,

July 2015,

August 2016,

December 2016,

January 2017,

February 2017,

March 2017,

April 2017,

and

June 2017.

r the

three

and

nine

months ended

September 30, 2017,

we recognized a loss of

$2,000

and a gain of

$1.8

million, respectively, compared with a gain of

$1.4

million and

$673,000

for the same periods in

2016,

respectively, related to the revaluation of our warrant liabilities.

Derivatives, Policy [Policy Text Block]

Derivative Liability

July 2015,

we entered into

$3.55

million

12%

Original Issue Discount Convertible Debenture due

January 18, 2016

with Acuitas (the

“July 2015

Convertible Debenture”). The conversion price of the

July 2015

Convertible Debenture is

$11.40

per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case

may

be. In

October 2016,

we entered into an amendment of the

July 2015

Convertible Debenture which extended the maturity date of the Convertible Debenture from

January 18, 2016

January 18, 2017.

In addition, the conversion price of the

July 2015

Convertible Debenture was subsequently adjusted to

$1.80

per share. The

July 2015

Convertible Debentures are unsecured, bear interest at a rate of

12%

July 2015

Convertible Debenture to

April 30, 2017

or until we completed a public offering, whichever came first. In

April 2017,

the

July 2015

Convertible Debenture was converted into

2,385,111

shares of common stock and the derivative liability was written off.

r the

three

and

nine

months ended

September 30, 2017,

we recognized a gain of

and

$132,000,

respectively, compared with a loss of

$3.5

million and

$6.3

million for the same periods in

2016,

related to the revaluation of our derivative liability.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued or Newly Adopted Accounting Standards

April 2016,

the FASB issued Accounting Standards Update (“ASU”)

2016

10,

Revenue from Contracts with Customers (Topic

606

)

(“ASU

2016

10”

), which amends certain aspects of the Board’s new revenue standard, ASU

2014

09,

Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU

2014

which is effective for annual and interim periods beginning after

December 15, 2017.

2016

will have a material effect on our consolidated financial position or results of operations.

March 2016,

the FASB issued ASU

2016

09,

Compensation — Stock Compensation (Topic

718

): Improvements to Employee Share-Based Payment Accounting

(“ASU

2016

09”

December 15, 2016,

and interim periods within those annual periods. Early adoption is permitted.

The adoption of ASU

2016

did

not

have a material effect on our consolidated financial position or results of operations.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Share-based Compensation, Stock Options, Activity [Table Text Block]

				Weighted Avg.
	Shares			Exercise Price
Balance December 31, 2016		244,046		$	39.06

Granted		-		$	-
Cancelled		(193	)	$	(245.47	)

Balance March 31, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance June 30, 2017		243,853		$	38.90

Granted		-		$	-
Cancelled		-		$	-

Balance September 30, 2017		243,853		$	38.90

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Balance at September 30, 2017


(Amounts in thousands)	Level I		Level II		Level III		Total
Certificates of deposit		106		-		-		106
Total assets		106		-		-		106

Warrant liabilities		-		-		41		41
Total liabilities		-		-		41		41

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Level III				Level III
	Warrant				Derivative
(Dollars in thousands)	Liabilities			(Dollars in thousands)	Liabilities
Balance as of December 31, 2016	$	5,307		Balance as of December 31, 2016	$	8,122
Issuance of warrants		2,405		Issuance of convertible debentures		-
Change in fair value		5,181		Change in fair value		10,596
Balance as of March 31, 2017	$	12,893		Balance as of March 31, 2017	$	18,718

Issuance (exercise) of warrants, net		269		Issuance of convertible debentures		-
Change in fair value		(6,950	)	Change in fair value		(10,728	)
Write off of warrants		(6,174	)	Write off of derivative liability		(7,990	)
Balance as of June 30, 2017	$	38		Balance as of June 30, 2017	$	-

Issuance (exercise) of warrants, net		-		Issuance of convertible debentures		-
Expiration of warrants		-		Expiration of warrants		-
Change in fair value		2		Change in fair value		-
Balance as of September 30, 2017	$	40		Balance as of September 30, 2017	$	-

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

	September 30 , 201 7
Expected volatility		93.56	%
Risk-free interest rate		1.62	%
Weighted average expected lives in years		2.54
Expected dividend		0	%

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual)			1 Months Ended			3 Months Ended				9 Months Ended
	Apr. 28, 2017 USD ($) $ / shares shares	Apr. 25, 2017	May 31, 2017 USD ($) shares	Apr. 30, 2017 USD ($) shares	Jan. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) shares	Jun. 30, 2017 shares	Mar. 31, 2017 shares	Sep. 30, 2016 USD ($) shares	Sep. 30, 2017 USD ($) shares	Sep. 30, 2016 USD ($) shares	Dec. 31, 2016 USD ($)	Oct. 31, 2016 $ / shares	Jul. 31, 2015 USD ($) $ / shares
Cash, Uninsured Amount						$ 6,800,000				$ 6,800,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares										2,255,381	1,178,821
Share-based Compensation										$ 191,000	$ 523,000
Proceeds from Issuance of Common Stock										16,458,000
Gain (Loss) on Conversion of Debt										(1,356,000)
Gain (Loss) on Issuance of Common Stock										(145,000)
Income Tax Expense (Benefit)						2,000			2,000	4,000	7,000
Warrant Liabilities, Noncurrent						41,000				41,000		$ 5,307,000
Repayments of Convertible Debt										4,363,000
Fair Value Adjustment of Warrants						2,000			(1,423,000)	(1,767,000)	(673,000)
Derivative, Gain (Loss) on Derivative, Net						$ 0			$ (3,500,000)	132,000	$ (6,300,000)
Amended Warrants [Member]
Warrant Liabilities, Noncurrent												$ 5,300,000
Class of Warrant or Right, Number of Additional Securities Called by Each Warrant or Right \| shares								0.2
Write-off of Warrant Liability										6,200,000
Warrants Not Subject to Amendment [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares								11,049
Domestic Tax Authority [Member]
Income Tax Expense (Benefit)										$ 0
Common Stock Issued for Investor Relation Services [Member]
Stock Issued During Period, Shares, Issued for Services \| shares						0			0	28,985	0
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		6				6				6
Chairman and Chief Executive Officer [Member]
Deferred Salary Settled by Shares				$ 1,100,000
Common Stock Issued for Settlement of Deferred Salary Balance \| shares				233,734
Gain (Loss) on Issuance of Common Stock				$ (83,807)
Acuitas [Member] \| January 2017 Convertible Debenture [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares					254,904
Proceeds from Issuance of Debt					$ 1,300,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Repayments of Convertible Debt				$ 1,300,000
Acuitas [Member] \| Amended Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares				31,167				31,167
Acuitas [Member] \| January 2017 Warrants [Member]
Warrant Term					5 years
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion					100.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 5.10
Acuitas [Member] \| December 2016 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares					137,883
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion												25.00%
Class of Warrant or Right, Additional Percent of Securities Called by Warrants or Rights Upon Conversion					25.00%
Shamus [Member] \| Shamus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares					14,706
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion					100.00%							75.00%
July 2015 Convertible Debenture [Member] \| Acuitas [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares				2,385,111
Debt Instrument, Interest Rate, Stated Percentage														12.00%
Debt Instrument, Face Amount														$ 3,550,000
Debt Instrument, Convertible, Conversion Price \| $ / shares													$ 1.80	$ 11.40
Several Investors, Including Acuitas and Shamus [Member] \| Convertible Debentures [Member]
Debt Conversion, Converted Instrument, Shares Issued \| shares				2,982,994
Gain (Loss) on Conversion of Debt										$ (1,400,000)
Accredited Investor [Member] \| Amended Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares								13,258
Public Offering [Member] \| Acuitas [Member]
Stock Issued During Period, Shares, New Issues \| shares				181,154
Proceeds from Issuance of Common Stock				$ 869,539
Public Offering [Member] \| Joseph Gunnar & Co., LLC [Member]
Stock Issued During Period, Shares, New Issues \| shares	3,125,000
Shares Issued, Price Per Share \| $ / shares	$ 4.80
Shares Issued, Price Per Share, Net \| $ / shares	$ 4.464
Proceeds from Issuance of Common Stock	$ 15,000,000
Over-Allotment Option [Member] \| Joseph Gunnar & Co., LLC [Member]
Stock Issued During Period, Shares, New Issues \| shares			303,750
Proceeds from Issuance of Common Stock			$ 1,500,000
Additional Shares Available for Purchase \| shares	468,750
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares
Minimum [Member] \| Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life										2 years
Minimum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life										5 years
Maximum [Member] \| Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life										7 years
Maximum [Member] \| Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life										7 years
The 2017 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares						2,333,334				2,333,334
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number \| shares						243,853				243,853
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant \| shares						2,333,334				2,333,334
Share-based Compensation						$ 32,000			$ 174,000	$ 191,000	$ 523,000
The 2017 Stock Incentive Plan [Member] \| Employees and Directors [Member]
Share-based Compensation						$ 32,000			$ 174,000	$ 191,000	$ 523,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares						0			0	0	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized						$ 127,500				$ 127,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition										1 year 7 days
The 2017 Stock Incentive Plan [Member] \| Nonemployees [Member]
Share-based Compensation						$ 0			$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross \| shares						0			0	0	0
The 2017 Stock Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										3 years
The 2017 Stock Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										5 years
The 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares						243,853				243,853
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Number of Major Customers										3
Sales Revenue, Net [Member] \| Customer Concentration Risk [Member] \| Three Customers [Member]
Concentration Risk, Percentage										90.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Number of Major Customers										5
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Five Customers [Member]
Concentration Risk, Percentage										96.00%

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) - Employees and Directors [Member] - $ / shares	3 Months Ended			9 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Sep. 30, 2017
Balance (in shares)	243,853	243,853	244,046	244,046
Balance, weighted average exercise price (in dollars per share)	$ 38.90	$ 38.90	$ 39.06	$ 39.06
Granted (in shares)
Granted, weighted average exercise price (in dollars per share)
Cancelled (in shares)			(193)
Cancelled, weighted average exercise price (in dollars per share)			$ (245.47)
Cancelled (in shares)			193
Cancelled, weighted average exercise price (in dollars per share)			$ 245.47
Balance (in shares)	243,853	243,853	243,853	243,853
Balance, weighted average exercise price (in dollars per share)	$ 38.90	$ 38.90	$ 38.90	$ 38.90

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Total assets	$ 106
Warrant liabilities	41	$ 5,307
Total liabilities	41
Certificates of Deposit [Member]
Certificates of deposit	106
Fair Value, Inputs, Level 1 [Member]
Total assets	106
Warrant liabilities
Total liabilities
Fair Value, Inputs, Level 1 [Member] \| Certificates of Deposit [Member]
Certificates of deposit	106
Fair Value, Inputs, Level 2 [Member]
Total assets
Warrant liabilities
Total liabilities
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposit [Member]
Certificates of deposit
Fair Value, Inputs, Level 3 [Member]
Total assets
Warrant liabilities	41
Total liabilities	41
Fair Value, Inputs, Level 3 [Member] \| Certificates of Deposit [Member]
Certificates of deposit

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017
Warrants [Member]
Balance	$ 38	$ 12,893	$ 5,307
Issuance (exercise) of warrants, net		269	2,405
Change in fair value	2	(6,950)	5,181
Write off of warrants		(6,174)
Balance	40	38	12,893
Derivative Financial Instruments, Liabilities [Member]
Balance		18,718	8,122
Issuance (exercise) of warrants, net
Change in fair value		(10,728)	10,596
Write off of warrants		(7,990)
Balance			$ 18,718

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details) - Warrant Liability [Member]	9 Months Ended
	Sep. 30, 2017
Expected volatility	93.56%
Risk-free interest rate	1.62%
Weighted average expected lives in years (Year)	2 years 197 days
Expected dividend	0.00%

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 3 - Related Party Disclosure (Details Textual) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended
	Apr. 30, 2017	Mar. 31, 2017	Jan. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Jul. 31, 2015
Repayments of Convertible Debt						$ 4,363,000
Proceeds from Issuance of Common Stock						16,458,000
Gain (Loss) on Issuance of Common Stock						(145,000)
Due to Related Parties, Current								$ 9,796,000
Amended Warrants [Member]
Class of Warrant or Right, Number of Additional Securities Called by Each Warrant or Right		0.2
Acuitas [Member] \| July 2015 Convertible Debenture [Member]
Debt Conversion, Original Debt, Amount	$ 4,300,000
Debt Conversion, Converted Instrument, Shares Issued	2,385,111
Debt Instrument, Interest Rate, Stated Percentage									12.00%
Acuitas [Member] \| December 2016 Convertible Debenture [Member]
Repayments of Convertible Debt	$ 2,900,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Acuitas [Member] \| Public Offering [Member]
Stock Issued During Period, Shares, New Issues	181,154
Proceeds from Issuance of Common Stock	$ 869,539
Acuitas [Member] \| Acuitas Warrants [Member]
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion								75.00%
Acuitas [Member] \| Amended Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	31,167	31,167
Acuitas [Member] \| January 2017 Convertible Debenture [Member]
Proceeds from Issuance of Debt			$ 1,300,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			254,904
Repayments of Convertible Debt	$ 1,300,000
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Shamus [Member] \| Conversion Of December 2016 Convertible Debentures Into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 1,300,000
Debt Conversion, Converted Instrument, Shares Issued		276,204
Shamus [Member] \| Acuitas Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			137,883
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion			100.00%
Shamus [Member] \| Shamus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			14,706
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion			100.00%					75.00%
Chairman and Chief Executive Officer [Member]
Deferred Salary Settled by Shares	$ 1,100,000
Common Stock Issued for Settlement of Deferred Salary Balance	233,734
Gain (Loss) on Issuance of Common Stock	$ (83,807)
Chairman and Chief Executive Officer [Member] \| Travel and Expenses [Member]
Due to Related Parties, Current				$ 223,000		$ 223,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 4 - Short-term Debt (Details Textual) - USD ($)	1 Months Ended		9 Months Ended
Note 4 - Short-term Debt (Details Textual) - USD ($)	Apr. 30, 2017	Jan. 31, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Repayments of Convertible Debt			$ 4,363,000
Acuitas [Member] \| January 2017 Warrants [Member]
Warrant Term		5 years
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion		100.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.10
Acuitas [Member] \| December 2016 Warrants [Member]
Class of Warrant or Right, Percent of Securities Called by Warrants or Rights Upon Conversion					25.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		137,883
Acuitas [Member] \| January 2017 Convertible Debenture [Member]
Proceeds from Issuance of Debt		$ 1,300,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Class of Warrant or Right, Issued During Period		254,904
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		254,904
Repayments of Convertible Debt	$ 1,300,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 5 - Restatement of Financial Statements (Details Textual)		3 Months Ended	9 Months Ended
	Apr. 25, 2017	Sep. 30, 2017	Sep. 30, 2017
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	6	6	6

EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 109 169 1 true 45 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://catasys.com/20170930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://catasys.com/20170930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://catasys.com/20170930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://catasys.com/20170930/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) Sheet http://catasys.com/20170930/role/statement-condensed-consolidated-statements-of-operations-unaudited-parentheticals Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet http://catasys.com/20170930/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited- Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Document - Note 1 - Basis of Consolidation and Presentation Sheet http://catasys.com/20170930/role/statement-note-1-basis-of-consolidation-and-presentation Note 1 - Basis of Consolidation and Presentation Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Related Party Disclosure Sheet http://catasys.com/20170930/role/statement-note-3-related-party-disclosure Note 3 - Related Party Disclosure Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Short-term Debt Sheet http://catasys.com/20170930/role/statement-note-4-shortterm-debt Note 4 - Short-term Debt Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Restatement of Financial Statements Sheet http://catasys.com/20170930/role/statement-note-5-restatement-of-financial-statements Note 5 - Restatement of Financial Statements Notes 11 false false R12.htm 011 - Disclosure - Significant Accounting Policies (Policies) Sheet http://catasys.com/20170930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies 12 false false R13.htm 012 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies 13 false false R14.htm 013 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-tables 14 false false R15.htm 014 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) Sheet http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-employee-and-director-stock-option-activity-details Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) Details 15 false false R16.htm 015 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-assets-and-liabilities-measured-on-a-recurring-basis-details Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) Details 16 false false R17.htm 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) Sheet http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-measurements-using-significant-level-iii-inputs-details Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) Details 17 false false R18.htm 017 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details) Sheet http://catasys.com/20170930/role/statement-note-2-summary-of-significant-accounting-policies-fair-value-assumptions-details Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions (Details) Details 18 false false R19.htm 018 - Disclosure - Note 3 - Related Party Disclosure (Details Textual) Sheet http://catasys.com/20170930/role/statement-note-3-related-party-disclosure-details-textual Note 3 - Related Party Disclosure (Details Textual) Details http://catasys.com/20170930/role/statement-note-3-related-party-disclosure 19 false false R20.htm 019 - Disclosure - Note 4 - Short-term Debt (Details Textual) Sheet http://catasys.com/20170930/role/statement-note-4-shortterm-debt-details-textual Note 4 - Short-term Debt (Details Textual) Details http://catasys.com/20170930/role/statement-note-4-shortterm-debt 20 false false R21.htm 020 - Disclosure - Note 5 - Restatement of Financial Statements (Details Textual) Sheet http://catasys.com/20170930/role/statement-note-5-restatement-of-financial-statements-details-textual Note 5 - Restatement of Financial Statements (Details Textual) Details http://catasys.com/20170930/role/statement-note-5-restatement-of-financial-statements 21 false false All Reports Book All Reports cats-20170930.xml cats-20170930.xsd cats-20170930_cal.xml cats-20170930_def.xml cats-20170930_lab.xml cats-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 39 0001437749-17-019351-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-17-019351-xbrl.zip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�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b!MBZ9O!!53OJN_,.JI=U"MOCY(DN? MN(%^T.RMW,^X=L_ ^.YSGW?+R 4JOZ/*8V+,N$"V[CHS(SNT2Y5#7Y4_D-(V IUV'6]MG&Y?SR*TPL<_,C!2D1H-XVAD)S,)9S5S4 A@!: M2"'I9Q]1XLG$\OR7HMS?>Q+R!*Z-=]$:2VN?NP3E*M._ 4JN)9R[C_.T]6%K MJCN=4)WT]*-GR>^:^Y@7.,K27W'2E/2:YU>X2)\C,,&(5+)B+\.5,#!ZB()Q ML-TG+0JMWX11O(L]\L84Q;G>TQ8E/]/+#'LBHI5"@G 90V-0JS[!G3O=\^ VD@ ;@?]\0;T#8\,9JGDN W]F,@0P<%2:2'J M/ QD)N^42K[)RZI@A""^^A$AD+9 M<1RMK4\H8G@$2ANMSGHR@I^!M"?%:+OFA:P UQCBPE)P*LB3#_2,-Z1 %;N/ MU:$#8)S?.FN8**F!AE6,JDSOTXU:G/3L1]^6;5<-"%3H8>I%+Q[95SB1! 63 M2Z!5B@P"!.](A4LX]NY/(:V!.% L@(+T$ ,&AM?D']+RE^L"XYN<3A0N*TU- M+NMN49/W@7&]N #FV9("A2)F#"HJ*-C)Z',IZP?T^3 _@R6VV3\D#FATI3[C M4]JH %#Z4%Z M6(V><1$]882;TVL&)DDP,^]P5)3H]7_3/V&RI2A/@>(1]I2OP52=_"(O;CA> MJ7FZIHLAC\S%98R_IKEYE>!H"\Y5$,NB'8Y8X9,X_F^KQK8A/!U(_@,4O>[H51OC6N@,AD* MS3.^'KZZ'LPKW2QSNGZCW!E 3Z*5YC_ MOS0=VA+9T;VSKX7)AI.?S[(:";[ MSJSWC//M8(RFJ)EQUKS#X9R;56IX8:1(R#RBRA'/ANXM?B1U\N3[J!B^-0QW M,#5S"P=VGN!C18H*,8-(@A?5K-U)-Q2-75M0JZF>A7[SEFFLWWQU_@VT+>'> M1Z^SF9%#E$VR#4SA%#P<&)KTV34&,Z1TC7)E#!\6,:+/0+_KJLEQV=0I.TKP M)UA6G;GOGBL273CS_?&WZ $7<"U\)V!#0C7_CU04 M5^CK\QGPZUOT&GHJL/"+ /=(30DF(^9LY"JE:F"]57"-E;4S68%]X[D_.@%, M"WZQ=I!WL9*.2 Q3*54L*$29@>$>Q%2*J-,&=R0O#D+KH7\=1!^O\O0?],[4 M7\==\NSE'+:%ISEG.'KTZ>WD3*/7AWV*";@I=1&?H19KM$=[<@DFO$B.X$71 MDSCXU0>M/:QV0Q5%5PG;&:ZSD_%\O4F> #:Q#EC WOA%DC2PV:O], 6.EJ18 M((@RGSR+.KA7T]79,I!G]!,)O+RUJ=CWC^I:^!G8NII/&&D9X";19%&(A)V/ MT2G&%HD--]-95\F8*&KYK#K<>:?/Q>.P]M%.-O MGS8I<7$'/:0WX&N^@B#U65YL7$M%KD(\H4L-85Y\ (_#>UQ RJWY\@$.R-Q- M*L5=PP_F7/^ *(0/10LJ"_<_,Q9?46F!JW5,W@P)MM M$V;=6&PKE!/PXURGM3=6Q)Z5::,F_C>$&Y8;)48\B(GG/$SQ"B?;#%.L>[/= M,)>T.7?YKE-;[Y2,DO8&-LVQ-!H!#Z\)!3Y; &*HB]FLSC97(S=##7I3,1M: MG%OB;L+\+J0?<$[OU=E%GEPD:WJ:+5D&U&=<6V@$JT2QE^$2&!C=M7S7X)E- M/#I ((C4JO*:&#+0W// M1+*R*?&7F# MT&,G^2VX,>]2@WA@*#9SD A$ @ MFZ#CG\:B= MV/D9^LW;+]^^?7L.,5\\_OI/Z ]OW\[>\O]0"2N57HJWU8H4D&/Y3^C\#[,_ M_O&[V?FWYTQC?3?[ZOSWLV]__W73M@[;9ADDMU59T0_,(;)"#U1"^'ONUV]K MUWMHU;[RU@[Y6M%ECA2=<(Z)ZL2%E(5?<]Z<.TG+UDNO<_,@2X-M M=.PH5EZT^GUXSQ/U&+_]'8_L=R<\V>K0:RJ(_-LP*;I4F-Z_'\DY.=+U:%]F M8?]T/5]>X<6Q44&QM8E+D'A4]UD$P5NBZP/0:$/@" M'7C+ $& 11B"QFP@_9,3=X(YDR8",NALF2=*BM8L%P.EZHE-7\:FK\ Q> PX<.>*$<*%4T -$D].!-TV>H$EUPSQL;6NSY*,&V2CK>][D-LDC M1LLVR#[N>8Y\H!A$E,:F-&.>-.?#:U(\X.(YC7$Y+RZS*%V+[G%&8YC&2.C M\BF6W2R 98U'F) )H]D@5E@<(-Z+QVT.EAV6MAT3ZW4\IOM7I0TITZI;(25@ M910Y6X^#ON2\"K:;WD?%O&"%"!)V6VY2R@SOK$,]Q^^R(@A^=]S6.,MVVX1D M&22/WE#98SMO\(UWN1@AXHL2QM;;PB>D?UDA^1%XRX8OD1 73H MBL=R_A)-IKE\1Z\]6*[3,HXRJ'/P/D^N3JO@J#0U>%T7#>E\XZY3_'+ """C M]_#(Z;O$C1)?B0ZS1IJ-P;&)ZG%^_=YD:26.VQYH:F(P%@SI(RLO!5L'\C# MYN':UF@P-S\>FA4CYEL']/$[>,GH>Z%7#0Q&2/K_M&2-DBUS,(>7/3!.UA:D MCGN ?WODD(P1':9[#OE84]6>_LJ=III"J_G3)2E9!J6K.F&OR%ZDV]TTT$,1 MC'O7IST>K2V\36H,U_BTMKA0Z::XU5&MO/) 6Z),Z1CL*O9#=\+(V%D8J>HO MXIBN>8@#OJ'J@NJ&0E8I7=[61-F+QO003E3#10W@,273;1$Q.I@\RE&T)RVM MT0E2*'U 6(@6\P)?I2X^I2(=+6UKZQH%8P:Z1 'HB5RA#C@KNT"=LLNWR;2$ MI )1ADNU/%G#'8P-I**!W=M%2YX'!&!/+EV6 L.)/A>G8 "]@!>H)Y;F]-UN MW^0^VL%7%R]1D=01^7^CVA8G$%S:% 8D\-5\?]:_V_::/*[YU&CC!?=\P5 MCK)J%=/S05B/0@$K3V^2O?SQ*QOW19W&8#"*5M+24$IZ1G0M*BU(:3BM+)HV M)_*XV2 2)YL;HL'PD+*GX*,_W,&*)/KTU#\1R&DYZRMP7"A?=EWV=0]&8 "6 MG(>Z/X\X!L$PWDX_ "S8D>> 862("[XS)FT*'*?,6$ _9[C.2])]2Q6H%)VN MQMF4AD'HR] S+A9$NXIN!Q6>W;.#@U%58">TF9E$57 )E%-*0\;(&.:&W[\' M ]/5.EG8C#HQ]PWH[0':+ M]_P$X!&#[_?M79G)1)=SGJ6(I;!7DZ"#IG:DAPT91G(8Z$D(S2%?Q0+3PZR0 M1R7- $J]SE:.3J'"*$^.4).,I-2<$.%I:HKQE,QRO"V:8!<[Q,@TD;NIL)\:\#*'#!BZ$?6U&:2M/0M0+U,1V-Q)KXWK=M:8* MKV%EEU8Q;US>,M[G55KMKM,,%Y=T63V1XCA#^T K@[M%SVBN19B#1 PF:H!Z MOT_(V$@4>>->&&H9_( W8/3-G^"XV.L-IM+<6#SZA_4D)TV(=@L=XN6LLS1FCW-]Q3E>&X]R[: M0T4 -FQ&"7W^D]%,=:_E_D8RBD94<%TK5F^"=L9Z[6@\3PJMA4-37V:3P=,H#N"1>(*>4IT6&4>WWR=YQE_YF3E_P!1R7) M<<+] Q /_L%P*,&/N((!-(X0VPFVKS[O&(M.X%(?\=0 M4!PG%\^XB)[P^T^XB-,2WQ=I+'H'\ P]4*2E(I:?2Z"E(CDAXBR=<7K#(A_H M7:>H] Q$[Z(,\KK,T$N-#XHX0@C7&*$-H&3T&/19,O%]KIE1WRD+)QIRJJO8 M+$:<&DW_R&P]_Q'E6WH@AQ\N]Y42KII"">+4/5H=3?+X* %PK;EK)'B]L@X: MJ,7#/,>/(P+'YG<[*I6!HN9VCS#+AP4Y@"H"^;&ZS F0#TA/ HDYUT%OS9*\HRG+S;-;G?ZS[EQPWI5,7H M6Y6N89DL9%Y<(:$'_%%P=G:<-V9N..IP6*/\+/?\I(K[997&*UXIJ)F8 ME_W$%$ /6F.T:+<$RO_MYJ"TTJS.E,@RC"RV%13!0EFZ3NL\)-%QV:$ &X1S M94B\2M'$S!/EP&GVFA1+G,*>6M[D/'[=A9W"$1JN#!:6T75N-(;['XCJI*[1 MX9@XJL"I6UZ&ND^[6H Z%VNG F'OAMUH>Z5;=7_CD3?IPT&]WI[;TYN-"_-8 M.LQ.6RT)=41]RDY$/V]SGN#\):WXJ>J [H%;==B+LT#(>B[+,HZ/7"&/]%=\ MN2TKLJ;G'O'BD+4S61=]X[E>$@PF:H&:+P8[R)NM@TL0L+PJN--QD9:_T*6P M#^HIN!\O7 ,J1F[30TG?UP64GTDY&XRT'B.3W'B)PC'O)Q:*;AF%#V#5XAE$<4*8=8 MJ74R%#+YX*[E;,YKN]8A5MD>?L!"KX.,/JGXJL8]S^%4R<_TF,44\R/Y@('Z M-,-WN+K)8WKX@LKOC^0R*E?W!7E.$["1?BRAD,><[G,1N+U?T,O6,R-G*)S4 M(2C3X"X'*#D/--SC#"?ZHL$:Y;A"&<48OH7/,<4;;4M^+R8-PG05-1A_'R8^ MRZ48$)]SZR% B-WJLIL\P9_^$XOCQ03MS$."#L?S%0O$H2(&%E&XH8* !-PD MRBQR+QD?\%,*,IE7X(8M%(S^9L9R<3B<)['8 V5N\H&$0L!)HLJ>$%'2UU%: ML.034%F.;@U;81J2P?:CHJ=[QO4;2=V#@'E4M15JC".L@T=6RX3D),IZD%?N M-65OQ*/H9V/-Z"=>L=:(08(4A2PC0WQP.<>W^"G*..B>D#%)"X.9/AK)>;X: M (>:*?$T,&#BQ M9R#U@ *G=?>F5F#OLZVD-XF2>1:X-S9H2SVW\<198!IR%3RYLSN5X"9@RE8M M/LL' EE:@:'V-@\#7A(,B(\" 1,-#')YZ!@PR8/FP<-T^V/K1GZN(W.J8]F4 MQR&8OC9L(^1,=B1/7+ ;F]/@AQB"G3:=$)SIK&IE.1Y:\7K3,M+YL4E^65[D MR55:X)@N+HD/I$)S$U=(R;#.;4P-:.;0T0(W]XRT2HN9@V0WQ3D]"%;T'@E/ MH15!^(#:I$$O@&.DBB01799.8&OD)T&58"N=35)_5)O;I3KTH!NG.IK6ME"7 MG+&[F7),-8);I[.S&@C_T!YK.F\C=]L[DK<:6+S)BEN9[*VGH[E>I%V(YONH M#;QM;Y]Y!Z< >Z9$,(@BU_SND*?.?P-.<\,=#/0=K3QF\U.!SE&90O>F:%"SLP_9SF"(XWZ]B VA-_G%L '^O#T36>6EP MR>!UG1: &NJBCSKXPY6BVZZF 3$B#BXC7'6UE"!Z]$(*?)W:NY/JVK/Q_*0E M!'Y5)7+HRTSEW$6RKE$L-<;P,3F]S!0,[5 M$ =F;HD;B>WHU((- 3\49+M!?R497 C+&;J]O42O__5?_OC55V__5+=A_SK_ MTQ>S.LE@6J((G;]]^UM$7O*Z7&&4[^#D^0C%2^D5^DMTC]-?<3%CN7,N5U%: MK",>WGVY2O$2GJ'C;94^8S1?+M.8GULO(PIM1Y&@6VT 2V"_))+A"?-]'(24 MO64%N\@=%EUX!:V,CX,'H[D_#G)P@8Z"_9PCBNSP_%X:E:N+/($_[_^Q39^C M#):W>M26=G_3-U!5.,Y-QY"XBZJ,IZ7Z+!!CUH:6QX''L^$.UB30U^/9H>AA!OO-ZP13I9A6@5S3A[DL ME; IE#7_@)]QOL60)N(I9S=]-56GW,]0T ;'=RUO-0*H@\'D-)WZ)!!CSHZ\ M2==.-)U'9 Y-+F4F74UNWXH@7,M:XZ/5P<-3YE;ZL5*=)?L>B%QQF%9L-A(T56AANA5%D>[R1"M=8D!#@QQ:-Z=3_MY1@89,;J(!(8OF;GGAI4G2)_Q M/66,K)Z$4A>STA+2H=U7F<"\^ A# +48($!A3,T)RU19*7K'""T9H6E+Z(;V M"%)M0DVDB E'QQ8BVF90R>4/FG5^E7L9E28:'-UYC2** 8C0'ZR7]W5 FNEZ M64*I&5:.!:-YD3ZEX!(']B P 0D(3[88_5P7,CK_XPQX] TO<51[-S#_CQ#E MB]0EDAC.A=\K4GT6*A_)1?R/;5K@^P+29U<[4 3519[ N\4&F@CN0/H#&%YR MU 'YNL6H8V1R37%"[Y@:@O?T^Q4]/S-OA$V-#'.5PFIT.KI8&$@@&<_FS\1T MR_[W-UR"L9W?<$3Y>5R \&VP[4%E\K;:'IR]FFFM\"R,88/]037NP6T;MM>. M#:OLX.3Z56,'%2D$>JBWC:$B.1A+7ZKI>6U!=.7ZKBY-8K*(1^)KIKD.@ ; MVB T 7@\C*VCQ=XOH$2)'Z&=R)2=QZP[C7G;AT\@&^VF%O W#KGI<[E\\_IJ M6GYO:OYN0:^VE+50FT22![6OB>GUM#.4:UEGEE0 %C*[:2_OB I#/(L!E+PJ MZ7'IFA179+NHEMOL@CL@"<5"H8NIF$B&=BXV#6SF;I74T!MOK#";J1*KB0G_ M/(>W=*(UYLLK'JO1:]G6Z&$:PB(>V7?02@UJ_<57[AXL=.YW#,Q149WCYNK0X(\#D[C,A;AJ8%1OL48T^$MD9 M9ZBE@1L2R]FA'1)(H&TJM,,54F6I(ZWD?N41[P(0+!NE0+OUM!B?;]*7!KE5 M33#I &-C0X?X@0"]2G< PT>M@&"2F=A[H1?:S/R3T M4C6IDX,EOD_Q.#&KWRV93:9#WC_7,4.^RGV6&%YWK-DM#D-U]]^RWS-/K-VQFB MPV]P#,ZJV<#;CK,8;-EL$"T6!W@0O"G++1:[ ?4T&?,(6 _EZ?&]3HU=>V0S MT&B[@6]P567$JS5T!6AO[$D7\9/AL;4CGCLK&&&>Q<\EI;C M%\%>IGAW/('\0^SU((%*'Q_IEG*3SS<8@G_RIPO0)^RD/Y!FQ7P@0#;[S?RXX31&*:)575@>3U^#)P[ MPJ0\-9H98H7=?N7X"B^JFYRN)Q94T@F.X!_AB9?50!2=4[3[&\JO,AQ?>[XR M0B:'&(?4&ER^ 1NT1V?6C19J_L'\&1A.01:LOAB2T=SV?6>(*G9PODUS?$,_ MBNSGXH;&]X?C =UGG*LAHI\ )F) 0Z4T%'*3J+/(MTDC@["B^ZBH=H]%1.]5 M,:N5OL_^-)QC3GL$8_.',B3WIQ*&"F*XH"XRJ),WZZ?PJ>?TYX988/C(T.,? MHC0'1^QY#O=0.!K-EYUB4T>"J-/%).AX8&C7H@:@$=TPTQHX&$/BCLU$.]+8 M.CT&QP3 ;T&++X VFXZM'5+I06D;4S8Y?2GS"PR_&+- L I-4]L_C(V?VD> M9UMZ"ZBK/]'+'LP%KN]GPI]\H@X>>ZXR\=/;CH;H*>KU-35UJ4)P?K3IHH.0@9W=, ML6*5#,-8PS1G@8QD[=A3SOXXSQ^_KTFQM^E"4-$"4LM./>1UG@58 -JB8L>)&D?4*E#S(Y17IHP^6,4]+C' MI_B 3TG#IZCF4UKC'>* 94/:B?79LEX6XX[RH?>=7KF]G0(8^W%]5;W(S*(5 M'.!O8&[L+=VQQR$P06;Z JJQH6-$+A]ILN4*J<-O(I.HCA(SYH45P01S:OMT\;'#?UG MZ_ (.HZ[.W9]I!_)L,7%XKA63A\&\$.<0@!-]'#@<-I@>A@20%?#>(-.$"8Y M.948..I.X70R9E4(3RFC9]%[DI7^I)D?2[S<9K?I4F1.TNAIGG)E"(*WC+'# MJ!BEBG5!H<')J,%CQG*]\_M$B\L,<6S0,)7N(.6M[1P M.=CYV42/3]0[\^W0%@&VG_DF6=SN6& $)]=>)H9)4TXO[W0YQA@GY34E:TZO M"$6=H4>8S$NCZ\C4Y#(0OI.2RW 9DX[<$HUCWD :<&Q_(8 BDIZ;@R4P4Q' MOGH2CZLSU'.@"6-I'2DP\$@B;6L:.-(WIO/K' <74I[DO"1:#)K()> ."ZM' M*'2Q?>RG0WO(M-A3'6$?\1S3P\66._TF<">.4WYF@%#G\]FW?SCGP<[GLV^^ MFD+ L](LJ9R83UCO6:7M^7[583O]G&'V%I@G%VM25.FOO"*<9BD4V\.;*DY+ M:(1:)(>KH\4_C#*V/:7$]3R%C.*39%H6-[02E^-E-VY?(&+Z ]C- MX= #R&/-#T6,# N".*/7L%H(=U^K$8*R0LL&F4X6BRDEL9!)X7#RBD%6^UVJ M\V=<0&:"BCUF;> X(\V-/MC><"$*QW6>,X4"/FLA(PXZ;%;T81X3;<:%/%$T MKEL?Z(&:A45#RC>H:AL]B=X>]0>PR>V7H !3ZS]6!D\,I4,X#P]7N!EVH.1Q65JA5X; MRY3T) >).0L]E]/ 48G!O?]F#585YJ7:GV="HX=IN0WQR,[SZ32@ M41=VV(N]"J.) ?<\%]2CZA="Y>D?>.EZIJN!XL6SN-_D<0%87V'^5R!Q)D.8 MEMS3 .7K(**#D\E1Q"W-AH>1M 8,^8/8P00>E]D'O,*+&%=^)(Q9E MFJ11L>N]KVE-Q# M\.4+)H@< D0"EX75F 453T@1:R]V@*!$UVGTM"V5>PB3D,IP6E%G#E1D M4L38L3DH\3,NHHR;N$E1WK 4G\R(MDVKJ*0H#*:I-!O"*).E'BCG6S!'![7X MP.-EC1&J46)R.3HKIFNZ1X>,ES4KTCTKTA-6_%"0[0;]E63P+6UQ>WN)7K^J M?WWU18=5S6_\7Z^^")&"TU"LB8TY\YU;,"9K#&EO(3E M.[PD!>;M'J-/N'S_J2HB4E!ZZ%&.Y;:'_!FT)^4MQ>^I>>,6[% >(!KG/'2& MF;_\B_GAWR3&TV'".!/A(A1@O?I ] B/T>A1Q M;N0%]FX+I^?Y\L?H9U)<;NE1>TW9W'=/E;>U@ MH,&"S8"C\$1829.?MV2M&5EQ@T]3NY)52J$_G+_]+:)_UH2G<(:^^QR*;"72 M0Q&//"_2\A=ZXLSCU3HJ?IFAEU4:KYIJ+/2NO-A6*">0OV:=@J]T16:HC#(, MQ5F><;[%LWW![J*M,SE#N(H#7*P'UB'1F%4'F:#[\KH]1!D]K;ZC_\_C8W^& M\0/9ROT\"-"+8C+"S$J:9P?T&Z@U4>9K0PY>KB+8[+@?5 M37@MR"Q9:XUI^E8U759<4L_T2^;K^C_%E&)Z3?_#U!+ M P04 " /@6Y+. ?@([<\G:!(E HV MBZA#D&J5?_T%N%2Q) )(< ,(\:47"2 S/R: 1*X__]?S*GKWA!**2?S+^\/O M/KQ_A^* A#A^_.7]_:UW='M\?O[^'4W]./0C$J-?WL?D_7_]Y[__V\__S_.^ MHA@E?HK"=P^;=W?++ Y1.>]^_#C3Y^^O_[UW?W=\;N/'PY_ M] X/O\_?XYP_.=/_(\'GZ)WC(B8YO_]Y?TR3=<_'1Q\^_;MN^>')/J. M)(\''S]\^'10C7Y?#N>_#=/MA/K@'PZ*7VZ'OGKTMT_YV,//GS\?Y+_=#J6X M:2![Z.'!__UZ<1LLTD,!/K%)$7>H@*E'%EY 8DHB'.;4>^Q#>^L$438R_P%C,7_C M,D&+7]ZSYU.O>C GZC^Z/C?=K)E04;Q:1^C]08W%^N +]H-R/&=F!'8+LM!S MBIA0E]!7E$4D4(#"?_+/2_9B>D?.<,Q$!?O1;442/7J@:>(':?6RR'] 4?$< MC5D%B1$7.Y*4T(E(K"^2A4\?"!84J;2HHM1L &L-]+J)!D.G7&$!K:@B?9N MZQPN^RNC:>V(MT(P&(?.@"$XSUP1"XC*3,92SG:@_GS0>"OKZ4X:DB#+_\'O M8^QOG&[8)7M!DI7F)13XH,%OG5ITP*Z9=7V&HN"[1_)T$"+,2?B>_X-#\GU- M@V$_^N<1HR'D=)Q%_N,+Y47X^[9*%I2HXRSAB^","9\?_0/YR6DVOB1^=L/W[^7[1IH$TZ M;B0BR6I%XMN4G=>W2Z91T*LLS6WT.&[:Y>&31B*_V-5OT)HD*7L[5T@:]RG( M\'%(;C03B7X]#DEG.$+),5NSCR01RVGCJ'$(O$&/F"NN<7KIKYI6N6S8."3^ M1J*,:7M) 9-8! 7CQB'R=Q1%_QN3;_$M\BF)47A.:882(;&*\4,3?8$>_:B@ MI,',)QDQ-&%WB<_WNMO-ZH%$#60U_MX=(YX,>:+:S*9^NP8I9@0@GE,WN.@ M 5>\'16/1E,N[.1R5$X4B$BU8C D']V 1'*>@*'XY 84,#L.&)7OW4!%J:&# M ?G!)4 @]STP,G]S"1GI-00,R8\N00*Z[("A^;M+T, -/F!\/KN!C]B\"%?; M'-%D 59@.":.Z+(@]P@<%4?46:!_"XZ+([JMQ(%OM9B/FX HLE2C'[L%O^U,[V05X[N&M^0*H[ MQ8O?()Z(@8KS>AWA]%>T>GAEYH4,'3]*\BA@ZR6+.) GB'VH .>?B?T[0F4P MRM&*:_-%H,IU0ABNZ>::09ZRWYW^*\-K_G%>,#O4XPT %$7D&Y>O,Y*H #A)VZ *V\^(A3:/&-\5FMJY[6?7"5YN%'XFQ]EB!T:N28J M8%!CIE&V"FWZ*$N7),%_H5#-CFB&!6SD]R4P"_NC+2!?[/G6F6(@"04],.V" M,N6%;TSWL5_L7VR#8^H57]+RO4!W^O@,7I*8P8ZXM>(N\6/J![F?@=$A"?Z' M3;*)&6G^"'3:^ Q=5XIWFWU:;[)IYH"[-6R2'%;;[AY]3.*R M&L(-OTD>"MEI]QAW@HE:+2OC:8%SXIL-N "5?-)6CW8%)W5.G,YU:>H!2?K2 M S>5NH+-N"FEEOJUYI32=JGI'".<6W92#-O9+Z<>-JF'41LS MV]1#*+L@)+?933V6LCLR34; J<=1=D>E>U"M!H^UZG'E/9&IZ>MAE+ M0RD[PM)IC[$UIK(C)MUW&%L#*_6 Z68U-1Q+MQV0%Q'E&GW^8CI<&%WK-YJ* MH.M(\)L-GCN/&=AHNX84CBS%:)MB(^9 #_.!'K.KVC#1LT=W]NA.R5BL.E]F M)^[LQ)V=N+,3=W;BFO=;SD[SU8KM -Q:0/%CS,[,P.>0H")A4 MBMD1V&+,$CFMRN$]$'6"@OR1[#=_4PND>G0/))VRS8]L$*),N$YP@@+V M) E-@.$]$'7&9/LX8W*R0C)B),/Z(")+8LSEH![ (R%&/;P'HO['CS-VE/!? M-(FLF#RMB?T2JI9TY> ^"&*ZVGKY-8N9^LPW4G)Q<2RA2#FZ#Y*RB//\@^:7 M!,_J@41V:T/5DA>3)![5"PGV--43D'B=/3#]C9W&*&':G!@GV;@>R##C$1,0 M<\O?P.M"%@<^/8^#*.,.\5+18ZOJ=NFO,HE8M7Q$'\2K*!ORM>K]4C:N!S+N MEHC]\$.AN<4!6S3LH.6QK&**@%-Z(^Y'?>*44WHA+D$0S44VK@+4IY MN$IN\.,RE9"M'&\)"U(W.&"&B>(G^7Y5A-7<8/KG%Q0'RY6?_"GG!3C-!H8V M6]ID$@:<9@5#BD4.F&$!&\H &, ,$VRP31\E:S])-[Q"N_0SB(<:(+Q4!EZA M*CWE@+-,USJ2? 7Q0--$K6SN2!W5QQD&\UR4:ZE*5C M346HWOG/9=9#8VK1IO M4Z#X'/5N7O._>D()KV>0YJ6)UIPLZ;I0CC=0,B_R8\6EI6F(.4*EHM(\R$0A M0D$Q!N5%76.F16PIU[#&S/'9NO'C1]DW>?5[0R1*]Y:&$0;(1'F]DFMNWY#* M@WB@6:)K!PS]LJG_1B8?V@\PP>0Z2X(E4]B/'A.4J^HOC5&*#Z8YWT".CA\Q M]2WWN!6:7.U;R)/1P!/-,$6YYSS.T"5J=J2!QLXY@6U8X)GU7YC0A\=DM49, M*(IH[H1OMOEU]\MF-^;:W^0&1>Y0VWG5XA"DN@SY*A/ D22]0\F*&RP5*H]T MK 6D*SZ;=+0!\G?1WD?;8._K,M9[:ZD4<:,U><[1G7-T;F_XW19A=S3)5[?D=.&ON\JIF!/ M<2<_6C>0U'B>=,IC.B\LS%'3\,\YE[PW9Y'OX?+:@$, AA-7N)[ASLPJ>/&B&2XZW47P#&",I"D@9*N(*7CV"" ::Y+5G-8-AG3 M8.0*E'(#$]$TYKB"BB0*4EA!W75)42<5$,5@E]%IX>9_*LT:A0L $"SFRF)0VE_UBHJZLD9@L*BJ M*H+1F$HC3W'!=UATJ"NK!F1#!!:4!&,RE9:F$MN/JIZ/*_*ABI?2JF#KRIZJ M97@')G^[@@U(8#I56P4C-976P,)M1E6PRI5-1AZ2$F@5S0=C,I4.R>++;DIEU82M"VRP4>86/W#+,<'+7(2*H)NR(APLC'GBM# X[< 11GAH$S?PZ5;#\D5@=',E]#K!^3*);-E4@FX<"58$B_0-@CSY7EA,<%.VV':Y U.&R*>DVZ4K$"LCH!^O\"=]H)N^< M!11 X&J$NTP=&8? 2$JM >& K+G260IC5U6%H44MQ! M]?/!*Z08O'\6O\M_Q:F^08MW_._[F_,MBVSQ^G1#OPO(ZJ#JT5C 1:L/Y<4D M1=XG+RD.!R]7UKUPRU]%E*C;H_:#"NXH7JV9"!W4F'C)7SE^[YOUR%!!!\,^ MO\^_;]/DLO$*%Q72JKKC=>JN63Y7W:95.K /0F36D#U"U&:33H3HN6[KE+5Q M^G8C-3]$*9/RJT5=.6V,93B/4U+S(4G8Z.VI/;"H(D#,AM[,'DB=3CO[*;1J MG_NDS]V]U62P:^D3BKB#YIE7JGKI^:Y3HA@Z?F';N3&Q+8V)YP:?1AB8&WQ: MU>"3^[C3#:_Y1V(F(E)IDHX=GW27V@/I]P,RW0"HD2CP9["H)\X;:=C43&/# MKJ3)I>0)!IHV.-FTR87.1W,#'T/D5[?A%X>WK)>PC,%;WGR@A6+[;>DE4L1V=.S+ J,Y1)P-N4N6;Z\ :-H$6[NRT=I:)L[R!,K6MVQW M]R"@E0\>SNS*$C.2;.M.0JDZ>,.5%03VQ0V2Z01&T9WLW!YRE2=?17E.56Z, M&&D=)CIJOO+W'N46RA0E*R]DBFY%"C!+631]G-QD^=NGF9&LKK(BRO(<+,ML M.IF=JM(] N(&0\ZF/,XY:P\>/3&5K#UXTH)B],3SQAQAPV3ZFTLY9&YE+,U9 M+W/6RYPJ\K931:9U8Y[S+.8\BSG/HF]+93CN: YSG@ M>0YXG@.>>XMNZ+LTO^62,I?FM\-#/_D@UME#WVAK /E$1O7&_^"QAV]_1!;> MHK*>>-L?;[\=T$6O]8" /Q*=+7GF _<7399_\B%^NY%+7:JX!U@A-KQ:\S@N4'^4$$PDN"0.6 MEX, ,J&>,#X3IWX2,ZFGURBY7;(C$\8)<-;X[)SY./G-CS)TM=@:)G:U44K8 M!4QIS1V?M?.8G8OHSG^&?2+5< /F8_2MMLTF)&;_#% -6QAC;1\S/L,O"%$< M08K1$R7?I/.%"<<:)>GF.N+MN)FVSD["-1<4F*#I3C>17O:$XHQ=%P+"-#*N M6L,X \^;73*M,K+8B?C%9W=77M\$Q32_]%RM\]MQ'+*-FJE2=J*&+9KK(D48@26M3^@>U4X'F..==ZN7;/;C>1VPVHK+ABZ9Q= M;C8X!MSQDCCN&%#=Q!J= G*[H2O0 /@EK>\9KJPD/9"@IDU7')":Z.@;LEU) M(M$#2LLDZTIJB1Y$G:_38-@LK^VL"9O>'0P,DN4%?/5 @IG;P=A87H%6#YL6 MCA4P4)97I]4#JIW%&8S59Q>P:A]7 5 M)EG;IW]%/H^X#*_B&Q1D"6_@Q 99X@3E> (R$X%PDP^F-KLB0 M#G*]WTA<<:BK01S^+N^*SUT#R_$L3/8:F4.4^CAB^B,C//.C(:W-@E=9:':6 M4MJQZ5_ A NG*#R/GQ!E%QA9_S_YV!YRC8WU(#P*PSR:S(_RXY0>/3' ^0(Z M(\EUE@1+=KXVT@.8URYA243H*O_8ZF9_TH$]$*+7R;Q.69L>Z-U(;:PJO/UR MURCA83I,D^);:K[K'OM1A,(OFPJ]<@Z]7Y-XUT.XD;F!WM6K$#42>9EQV*\6 M-9%^1>.I'RSW9X$Q:/?XX=D>_NM;\LUWG:S/*-NW:K!_7\-1H:CLM@5P[O M@2@+&_'N?XGB&[%U4QRVS51))O3Z"4^9@D@V**_:<28A1#^^!J*\^CB$VYUK&RQ?Z0^-1YAX MM!?W*42[]_"-B&\S5XO:[B0GK7%*O_3-C;!;$T0H6B^_9G'L)US3)1<7QQ** ME*/[("F+.,\_:'Y)\*P>2+PD,:HV2C%)XE&]D)"BIB*T)\4E_&[_#KY/EL[, M/D@M=>I?_3](LMW/&TEK'-GK>7B=/40X8'J$AT_,XB+*0V_ *.P9;ZDPS664266_YB#Z(5U$VY&O5F[AL7#]D,(VQN!Y< M)^P^4Z5!7:)&C4$VOM=U=K=$[(HC7,J[2V^SA#W8SNB.Y M]5)^;="8U@>1"4ZY@7)KW*D^Q\M*.XK1)JM7E5D)](;=W''NCFM$%SK< -L M;PAQE!N+=\:TTV=^(J+P+"$K[@+/"A?-U>)E NO1BO,CXK:/9QO]NM_$%3T M@6D<8Z8.Z3V#+_=L2K]*PTB3&"O[$[XD'];7TC@+TLAU< ]IXVR&U15/[670@0'^5*. D%QQ3/+-^0;3/[^@.%BN_.1/ MN60#I]G T&9+FVR_ 4ZS@B'%606880$;I7//?T3"W44RQ:HU\[K-BXH346.8 M<=E@.@%*UKP=^Z6_DDN4>*@!PLL+YBM4I4HY<):)VN4/Z:A0596A M;B 1K16]AYAY]HN#TL MG/--"]'TQD]1[E,(=R<(B"G9 ^QAD^_(TN-'-=QDOX:=4W;WL]>&8O \HU^% M'2\TQ4%^6B8;Z6DD'6N@]43I%"PCD)HS(RY)[DI!86X,H75W \]4Z(4]%S23I 028,3X;^T$6DA4@'FB"Z&>\RE92M!O' M&" 5QVI2F\:,3RK74E]$W<@[VZO&&V !U ?V)1\:#7/M8$;^6;3Z(H_)T!6[ M=Q]%$2F4@#S?5[HNE./'9X''>B@L=TU#S!$J%97F00:(34B 4$BYYQH26PR> M9[C_5@-Q#4'*(9IFC9MN82-<>S@L;.)4Y[ZYPIHK]QL,E%WTS1$3?T/J)" M[=L-N2ZVK=P8GO_Q&_?-Q(^%R5MD:>_S%9.$:AOA5A3P*(RY8I]/[^]Q ;1: MU9.OW DQ,'8O7S=)",OB;#D#]#PNEM#7A%!A-=K^WS1EX'XK7'_L5O7,3AOV MSSO"?W25I33U8YXA5TC-0&A"7V\UQ%2ZN><6A3@$F;V&?)4AX![4PO'PDADF M#+B(R2M6F0RM/IYO7+J:,AYE3#>--\L$2?*4-GZ_4QC?I&,M(%VQ0*6C#9 _ M5X^?J\=+N[L76\5)EFQO&/4M)*_95%2:$C*C\Q"CNY",TDOT+?]5*S:WDXVS MM]?OD9?*V-5=V(4/W_"S37A5U7R,49:S!XI#S&M0[8Q3LLU"-7Y\%NYPRBDY M9\KL$PXS/Y*0+QUK >F_XW19U:>C2[R^(Z=QJHKP:OD4&;O3*D<>M*AJ8[S3 M@Z&:]7-C@SU<7OL."J-(6+"7*Z!(T^](9T^5.S"I\UZ)9+CH M;N
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